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Abstract 
AGING EXACERBATES NEUTROPHIL PATHOGENICITY IN  
ISCHEMIC STROKE 
 
Meaghan Anne Roy-O’Reilly, M.S. 
 
Advisory Professor: Louise McCullough, MD/PhD 
 
Ischemic stroke is a major cause of disability and mortality worldwide. As 
most patients cannot receive the currently approved therapies for ischemic 
stroke, novel treatments are critically needed. Cerebral ischemia causes 
irreversible tissue damage, referred to as the “tissue core”, which is surrounded 
by a salvageable penumbral region. Excitotoxicity, oxidative stress and 
inflammation can further damage this “tissue-at-risk”, resulting in even greater 
functional loss and poorer injury outcomes.  
Aging represents the single strongest risk factor for high mortality and 
poor outcome after stroke in patients. This phenotype is also seen in animal 
models, with aged mice experiencing higher mortality and poorer recovery than 
their young counterparts. Our lab has recently shown that bone marrow 
transplantation from young mice into aged mice improves functional outcome 
after ischemic stroke, whereas aged bone marrow transplantation exacerbates 
secondary brain hemorrhage in young mice. However, the identity of the 
deleterious factor present in aged bone marrow remains unknown. 
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Bone marrow is the main site of neutrophil differentiation, maturation and 
storage. Neutrophils, innate immune cells with a rich arsenal of anti-bacterial 
functions, traffic to the brain in large numbers following ischemic stroke. Age has 
previously been reported to impair neutrophil protective functions (phagocytosis, 
directed chemotaxis) and exacerbate neutrophil-driven inflammation (increased 
reactive oxygen species generation, impaired neutrophil clearance). However, 
there are currently no published studies on the effects of age on neutrophil 
function and neutrophil-associated brain tissue damage after stroke.  
Neutrophils are believed to exacerbate brain tissue injury in ischemic 
stroke via the release of degradative enzymes and reactive species, leading to 
blood-brain-barrier breakdown, secondary tissue hemorrhage and direct tissue 
damage. In light of this data, neutrophil-mediated damage has gained 
significantly interest as a potential therapeutic target in ischemic stroke.  
Despite success in animal models, clinical trials of anti-neutrophil 
therapies for ischemic stroke have been unsuccessful, due in part to the limited 
specificity of available treatments and the tendency to test therapeutics in young 
animals only. We believe this lack of specificity and the failure to include aged 
animals in pre-clinical studies may have obscured the true contribution of 
neutrophils to stroke pathology. In recent years, administration of the monoclonal 
antibody anti-Ly6G has been found to specifically and robustly deplete 
neutrophils in mice. Encouragingly, our early work confirmed that post-stroke 
anti-Ly6G treatment results in a transient decrease in circulating neutrophils, 
x		
making it a promising tool for testing the role of neutrophils in acute ischemic 
stroke pathology.  
In this dissertation, I hypothesized that age enhances the pro-
inflammatory functions of neutrophils after ischemic stroke, directly contributing 
to the poorer outcomes seen in aged animals. I tested this hypothesis by (1) 
examining the effects of age on neutrophil inflammatory phenotype in vivo and ex 
vivo, and (2) directly assessing whether neutrophil depletion had a differential 
treatment effect in young vs. aged animals following ischemic stroke.  
These studies not only examine the utility of post-stroke neutrophil 
depletion therapy in young and aged animals, but also provide new insight into 
the changing function of injury-induced inflammation throughout the lifespan. In 
addition, we demonstrate that neutrophils from aged animals exhibit altered 
behaviors, including an impaired clearance phenotype, greater sensitivity to 
inflammatory stimulus and a higher capability for reactive species generation.  
In this body of work, I have (1) examined neutrophil-activating cytokine 
levels and neutrophil-associated gene pathways in human stroke patients, (2) 
advanced scientific knowledge regarding the influence of age on neutrophil 
function and neutrophil-related damage after ischemic stroke, (3) and improved 
clinical translatability by testing the utility of post-stroke neutrophil depletion in 
both young and aged animals. 
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1.1 The Heavy Burden of Stroke in Society 
Stroke is the 2nd leading cause of death worldwide, affecting more than 15 
million people annually.1 Stroke is responsible for 1 in 20 deaths in the United 
States, with particularly high mortality seen in a region of the southeastern United 
States known as the “stroke belt”.2 This region, which includes parts of eastern 
Texas, experiences 30% higher stroke mortality than the rest of the nation.3 The 
incidence of stroke around the world is tightly correlated with the incidence of 
several stroke risk factors, including hypertension, hyperlipidemia, diabetes 
mellitus, cigarette smoking, atrial fibrillation and cardiovascular disease.2 
Patients who survive their initial stroke often experience permanent and 
profound morbidity, as the brain is critically important to all human functions and 
has limited ability to regenerate. Stroke often leaves patients with extensive, life-
altering dysfunctions, including weakness, paralysis, loss of speech, 
incontinence, cognitive dysfunction, emotional lability and pain.4 Stroke also 
places a heavy burden on the families of stroke patients, with stroke caregivers 
reporting high levels of stress and depression.5  
Due to its high incidence and extensive sequelae, stroke now represents 
the leading cause of disability in the United States.1 By 2030, another 3.4 million 
adults in the US will experience a stroke, increasing stroke prevalence by more 
than 20%.6 The overall cost of caring for these stroke patients is projected to 
reach upwards of $183 million dollars, driven largely by longer life expectancies 
and a concomittant increase in our aged population.6  
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1.2 Ischemic Stroke Pathophysiology & Current Treatments 
 A stroke occurs when blood flow to the brain is compromised. Bleeding 
into the brain results in a hemorrhagic stroke, whereas ischemic strokes result 
from the loss or blockage of blood flow within the vessels supplying the brain.2 
This work will focus on ischemic strokes, which account for approximately 87% of 
all strokes.2  
Despite the high prevalence of ischemic stroke, there are currently only 
two approved treatment options: (1) mechanical clot removal or (2) 
pharmacological clot dissolution with tissue plasminogen activator (t-PA). 
Unfortunately, clot removal procedures require fast access to high-level 
endovascular care within six hours of stroke onset, which is not a reality for the 
vast majority of stroke patients. Although pharmacologic t-PA therapy is more 
widely available than mechanical intervention, t-PA can only be utilized in large 
vessel ischemic stroke. However, the treatment window of t-PA and mechanical 
retrieval is narrow (3-4.5 hours and 6 hours after symptom onset, respectively).7 
Due to this brief treatment window, the vast majority of ischemic stroke patients 
(>90%) do not receive t-PA or interventional surgery, leaving them with no viable 
interventions in the acute setting.  
Although many effective candidates have been identified in pre-clinical 
studies, all prospective treatments have failed to provide significant clinical 
improvement in stroke patients in Phase III clinical trials.8 If we are to reduce 
stroke mortality and improve quality-of-life in stroke survivors, novel therapeutic 
targets with significant translational potential are critically needed.  
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To design effective clinical targets for stroke treatment, it is important to 
understand the underlying pathophysiology of cerebral ischemia. Ischemic stroke 
results in a permanent core brain injury, defined as tissue where cerebral blood 
flow has been reduced to <20% of baseline. As neurons are exquisitely sensitive 
to ischemia, cell death occurs rapidly at the core of the ischemic brain due to 
acute energy failure, resulting in ionic disequilibrium, mitochondrial dysfunction 
and breakdown of cellular components.9  
Although the tissue core is thought to be irreversibly damaged within 
minutes of stroke onset, the area surrounding the core region experiences an 
intermediate reduction in cerebral blood flow reduction.10 This territory is known 
as the ischemic penumbra, characterized by regions of dysfunctional cells that 
may recover once blood flow has been restored.11  
Both approved therapies for ischemic stroke (t-PA and clot retrieval) are 
targeted towards recanalization, which removes the vessel blockage and allows 
the return of blood carrying oxygen and glucose to the injured tissue.12 Although 
these interventions can offer significant benefits to patients who arrive quickly to 
skilled medical facilities, their narrow treatment window reflects their primary 
method of action – reducing the severity of the primary ischemic injury.  
Unfortunately, even when blood flow is restored via interventional therapy 
or natural recanalization, the compromised tissue of the penumbra remains 
endangered due to a wide array of secondary damage pathways initiated during 
the primary injury.9 As this secondary damage takes place over a longer period 
of time (hours to weeks) compared to the primary ischemic insult (minutes to 
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hours), it is believed that therapies targeting secondary damage may have wider 
therapeutic windows. In particular, excitatory neurotoxicity and inflammation have 
been extensively studied as promising targets for ischemic stroke treatment.13, 14  
Excitatory neurotoxicity is caused by a massive release of glutamate from 
dying and damaged neurons, resulting in the widespread activation of neuronal 
receptors that eventually results in profound cellular dysfunction and apoptosis.11 
Experimental studies have found that targeting these excitatory neuronal 
pathways, known as neuroprotection, can reduce cell death and improve 
outcome after injury. Particularly well studied are N-methyl-D-aspartate (NMDA) 
receptors, which have been shown to mediate glutamate-induced cell death.15, 16  
Preclinical studies found that NMDA receptor blockade was highly 
neuroprotective after stroke in young mice.17 Yet despite success in animal 
models, all clinical trials of NMDA antagonists for ischemic stroke have failed, 
with one study reporting a trend towards potential neurotoxic effects of the 
treatment after stroke.18-22 Subsequent work in experimental models found that 
NMDA antagonism after cerebral ischemia induces neuronal apoptosis and 
suppresses brain tissue regeneration, or neurogenesis, which is critical for the 
restoration function after ischemic stroke.23 This is due to the fact that, despite its 
harmful role during injury, the beneficial role of NMDA receptor signaling in 
normal neuronal physiology is integral to the healthy brain.  
These results, and other failed trials of “neuroprotective” agents targeting 
components of normal neuronal physiology indicate that these strategies are 
largely ineffective and potentially unsafe for clinical populations.20 In light of this, 
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we believe that targeting of other secondary injury mechanisms that do not 
directly affect neurons (such as post-stroke inflammation) may result in greater 
translational success.  
 
1.3 Ischemic Stroke-Induced Inflammation 
Inflammation after stroke is caused by several factors, including (1) 
cellular activation and release of pro-inflammatory molecules from glial cells, 
endothelium and neurons, and (2) activation and recruitment of circulating 
peripheral immune cells.9 Following stroke onset, an array of danger associated 
molecular patterns (DAMPs) and inflammatory cytokines are released from dead 
and dying cells.9 Microglia, the innate immune cells of the brain, are activated 
and release cytokines and chemokines, potentiating both the central and 
peripheral inflammatory response.24 Inflammatory mediators generated in the 
brain gain access to the periphery via the (1) cerebrospinal fluid outflow tracts, 
(2) the systemic circulation via a disrupted blood brain barrier and (3) the 
glymphatics, a perivascular system for lymph circulation in the brain.9 In concert, 
these brain-derived DAMPS, cytokines and chemokines initiate the mass 
activation and recruitment of peripheral immune cells into the injured brain.25  
The earliest peripheral immune responders are neutrophils, followed 
closely by monocytes/macrophages.4 In later injury stages, the body mounts an 
adaptive immune response characterized by the activation and infiltration of 
lymphocytes.26 Pre-clinical studies have shown that the peripheral immune 
response can affect ischemic stroke outcome.8, 9 In addition, immune activation 
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and leukocytosis independent of infection (increased white blood cells in 
circulation) after stroke is predictive of poor outcome in patients, including higher 
mortality, poorer functional recovery and extended hospital stays.8, 27, 28 In 
particular, studies have found particularly robust associations between increased 
circulating neutrophil counts, higher neutrophil gene expression, and poor 
outcome after ischemic stroke.8, 28, 29 
 
1.4 Neutrophil Biology 
 Human blood is rich in neutrophils, which make up approximately 60% of 
our normal circulating immune cells. As neutrophils are typically very short-lived, 
new neutrophils are constantly produced in the bone marrow during a process 
known as granulopoiesis. Granulopoesis occurs on a massive scale, as humans 
are estimated to generated approximately 1011 new neutrophils every day, with 
even greater production under conditions of injury or infection.30 The 
development of all blood cell lineages begins with hematopoietic stem cells 
(HSC). Based on the levels of survival and differentiation factors (such as G-
CSF, discussed below), HSC can give rise to common myeloid progenitor (CMP) 
or common lymphoid progenitor (CLP) cells.31 CMP cells then further differentiate 
into monocyte erythrocyte precursor (MEP) or granulocyte monocyte progenitor 
(GMP) cells, followed by GMP differentiation towards either a 
monocyte/macrophage (monoblast) or granulocyte (myeloblast) lineage. 
Granulopoiesis begins with myeloblasts, which are capable of differentiating into 
the three types of granulocytes: neutrophils, eosinophils or basophils. Cells then 
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pass through the promyelocyte, myelocyte and metamyelocyte stages, becoming 
fully committed to the neutrophil lineage during the myelocyte-metamyelocyte 
transition.32  
Granulocyte colony-stimulating factor (G-CSF) is a major regulator of 
neutrophil production from progenitor cells, where it stimulates hematopoeitic 
progenitor proliferation and upregulates the expression of neutrophil-biasing 
transcription factors.33 During conditions of acute inflammation, G-CSF also 
facilitates the release of neutrophils from the bone marrow (where 90% of mature 
neutrophils reside) into the circulation via the inhibition of the bone-marrow 
retention CXCL12 ligand/CXCR4 receptor pathway.34 In addition to suppressing 
neutrophil marrow retention, G-CSF actively promotes neutrophil mobilization by 
stimulating CXCL1 production in endothelial cells and megakaryocytes. CXCL1 is 
the ligand for CXCR2, a highly expressed neutrophil chemotactic receptor.35 The 
lung microvasculature also contains a significant pool of mature neutrophils, 
which are released into the circulation during inflammation as a result of CXCR4 
inhibition.36 
 Neutrophils utilize four major inflammatory defenses to kill invading 
pathogens: phagocytosis, degranulation, neutrophil extracellular trap release 
(NETosis) and reactive species generation. In conditions of excessive 
inflammation, as seen in overwhelming infection and extensive tissue injury, 
these defenses can also exacerbate tissue damage.37  
Neutrophil phagocytosis is an important component of the immune 
response, characterized by the rapid uptake of microbes opsonized with IgG or 
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complement factors into neutrophil phagosomes, which contain destructive 
reactive species and hydrolytic enzymes.38 In conditions of excessive 
inflammation, phagocytic receptors on neutrophils encounter large complement 
or immune complexes that they cannot ingest, a phenomenon known as 
frustrated phagocytosis.37 As a result, neutrophils release massive amounts of 
granules within the vasculature, resulting in vessel degradation and tissue 
hemorrhage.39 This type of uncontrolled neutrophil granule release has been 
implicated in secondary tissue injury in both infection and inflammatory 
diseases.37 
Neutrophil degranulation occurs when immune activation stimulates the 
fusion of neutrophil granules containing an array of proteins with neutrophil 
phagosomes (for intracellular killing) or the cell membrane (for membrane 
presentation or extracellular release). During neutrophil development, they 
sequentially acquire four types of granules with distinct cargo; azurophilic 
(defensins, elastase, myeloperoxidase), specific (metalloproteinases, lactoferrin), 
gelatinase (arginase, lysozyme, gelatinase) and secretory (alkaline phosphatase, 
membrane receptors).31 Upon inflammatory stimulation, neutrophils release their 
granules in the reverse order. Therefore, although minor neutrophil activation is 
capable of inducing the release of secretory granules, the release of azurophilic 
granules requires stronger stimulation.40 Early neutrophil inflammatory responses 
consist primarily of the release of secretory, gelatinase and specific granules, 
which contain proteins that facilitate cell adhesion, migration through tissue and 
pathogen killing.  Azurophilic granules represent the last line of defense in 
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neutrophil degranulation, and the bactericidal proteins and destructive lytic 
enzymes they contain can cause significant damage to surrounding tissue.41 
Neutrophils can also release neutrophil extracellular traps (NETs) made of 
decondensed chromatin studded with neutrophil granules.42 NETs carry a variety 
of neutrophil proteins, including neutrophil elastase (NE), matrix 
metalloproteinase (MMP-9) and myeloperoxidase (MPO).42-44 Although NET 
formation is an anti-bacterial defense, excess NET formation can cause 
extensive damage to host tissues, including vascular injury and clot formation.45-
48 NET release is dependent on very high levels of intracellular oxidative species, 
suggesting the two processes are physiologically coupled.49, 50  
 Although neutrophils possess the capability to cause tissue damage via a 
wide array of functions, their production of reactive oxygen species (ROS) and 
the resulting oxidative damage to tissues ris a powerful potential mechanism for 
exacerbated secondary injury after ischemic stroke. Neutrophils generate large 
amounts of ROS during their respiratory burst, including (O2*), hydrogen peroxide 
(H2O2) and hydroxyl radicals (HO-).51 Hydrogen peroxide can then react with 
chloride and iodide (halide ions) to produce anti-bacterial hypochlorite (HOCL) 
using an enzyme called myeloperoxidase (MPO), abundant in neutrophil 
granules.52, 53 
 In comparison to other cells, neutrophils from both mice and humans have 
low oxygen consumption and mitochondrial mass at rest.54, 55 Upon exposure to 
inflammatory stimuli, neutrophil oxygen uptake and glucose consumption rise, 
accompanied by increased intracellular levels of ROS, results in the phagocyte 
11		
respiratory burst.56, 57 The respiratory burst is largely controlled by the NADPH 
oxidase complex of proteins, consisting of both cytosolic (p47phox, p67phox, 
p40phox) and membrane-bound (gp91phox, p22phox) subunits.58 Upon 
neutrophil activation, NADPH oxidase localizes to both specific granules and the 
neutrophil plasma membrane, allowing for electrons in NADPH in the cytosol to 
access oxygen and resulting in the formation of superoxide anion.58 Superoxide 
is degraded to hydrogen peroxide, which is freely cell permeable and can 
mediate intracellular and extracellular effects, including inflammasome activation 
and type 1 interferon signaling.58, 59  
In addition to the NADPH oxidase complex, inducible nitric oxide synthase 
(iNOS) also plays a role in neutrophil radical generation via the production of 
reactive nitrogen species (RNS) (Figure 1). Although both ROS and RNS are 
important components of the anti-bacterial response, the production of excess 
reactive species has been implicated in the pathology of many diseases, 
including ischemic stroke. Studies have shown that nitric oxide (NO) produced by 
iNOS contributes to injury after ischemic stroke.60-64 Using bone marrow 
chimeras, Garcia-Bonilla et al. recently determined that iNOS from infiltrating 
neutrophils was sufficient to exacerbate brain tissue damage after ischemic 
stroke.65 However, as all studies of pro-oxidative enzymes have all been 
conducted using young male mice, the contribution of these factors in aged 
subjects remains largely unknown.  
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Figure 1. Schematic of the neutrophil oxidative burst. A series of pro-
oxidative enzymes (in red) are responsible for the generation of reactive oxygen 
and nitrogen species, while anti-oxidative enzymes and mediators rapidly 
facilitate their detoxification, preventing excessive damage to healthy tissues. NO 
= nitric oxide, iNOS = inducible nitric oxide synthase, NADPH = nicotinamide 
adenine dinucleotide phosphate. 
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1.5 The Role of Neutrophils in Ischemic Stroke 
Neutrophils represent a likely culprit in ischemic stroke pathology due to 
their extensive pro-inflammatory functions (Figure 2).8 Recent studies using in 
vivo two-photon microscopy have shown that neutrophils are the earliest 
peripheral responders after brain, capable of migrating and adhering to the 
nearby cerebral vasculature within minutes of the initial injury.66 Following 
adherence, neutrophils can transmigrate across the damaged blood-brain-barrier 
into the injured parenchyma, where they release a wide array of inflammatory 
mediators that orchestrate the recruitment of subsequent waves of immune 
infiltration.8 Under normal conditions, neutrophils play an important role in 
protection against infection and the resolution of tissue injury. However, if 
neutrophils persist in an injured area, they contribute to chronic inflammation -- 
characterized by over-recruitment of monocytes, high levels of pro-inflammatory 
mediators and continual tissue damage.67 
Neutrophils differentiate and mature in the bone marrow prior to their 
release into the bloodstream. Under basal homeostatic conditions, neutrophils 
have a very short circulating half-life, returning to organs for programmed 
apoptosis and clearance within 24 hours.68 However, once neutrophils in 
circulation have been activated by danger associated molecular patterns 
(DAMPs) or cytokines, the apoptotic programming is halted as neutrophils traffic 
to the inflammatory site.68  
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Figure 2. Neutrophil activation and recruitment following ischemic stroke. 
(1) Following stroke, neurons and glial cells within the brain initiate inflammatory 
cascades that result in disruption of the blood brain barrier and (2) production of 
inflammatory cytokines. These pro-inflammatory factors diffuse into systemic 
circulation and result (3) in the upregulated production and release of neutrophils 
from the bone marrow via decreased CXCR4/increased CXCR2 expression and 
(4) pro-survival and pro-inflammatory signaling cascades in circulating 
neutrophils that facilitate their activation and migration across the endothelium 
into the brain (5), where they can initiate a wide variety of damaging processes 
that further exacerbate tissue damage (6).  
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Within tissue, neutrophils have several important defensive functions, 
including phagocytosis, oxidative burst, formation of extracellular chromatin traps 
(NETs) and degranulation (as discussed above).42, 69 Extracellular levels of 
myeloperoxidase (MPO) and neutrophil elastase (NE) are elevated in the serum 
of stroke patients, consistent with high levels of neutrophil activation and 
degranulation.70  
Many pre-clinical studies have shown that blocking immune cell adhesion 
molecules (E-selectin, P-selectin, ICAM-1, MAC-1) or stimulatory chemokines 
and their receptors (MCP1 and CCR2, CX3CL1 and CX3CR1) results in reduced 
neutrophil infiltration and infarct volume following stroke.71-85 Unfortunately, when 
similar therapeutic strategies have been attempted in clinical trials of ischemic 
stroke, no benefit was seen in patients.8 This is likely due, in large part, to the 
fact that many of the targeted molecules are expressed on a variety of immune 
and non-immune cells, leading to a high degree of non-specificity and 
contributing to unwanted side effects including increased infections and 
secondary hemorrhagic transformation.  
A recent study examined ischemic stroke in young mice deficient in 
neutrophil-specific Mcl1, a protein essential for neutrophil survival during 
differentiation. This neutrophil knockout model has allowed for the most specific 
assessment of the role of neutrophils in ischemic stroke to date.86 The 
investigators found no improvement in neurological deficits in Mcl1 knockout 
mice, despite reduced neutrophil infiltration into the brain.86 As improved 
functional outcome represents the most important goal of ischemic stroke 
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therapeutics, these results suggest that neutrophils do not play a role in 
exacerbated tissue injury following ischemic stroke.  It is critically important to 
note that the Mcl1 study (and all other previous anti-neutrophil studies for 
ischemic stroke) utilized only young animals (2-3 months of age). However, 
ischemic stroke is largely a disease of aged patients, and age significantly 
increases both stroke incidence and the likelihood of death or significant disability 
after stroke. It is therefore critical that studies investigating potential therapeutic 
targets for ischemic stroke be replicated in aged animals, as age represents a 
critical biological factor in stroke pathlogy.2  
 
1.6 Ischemic Stroke and Aging 
One of the main barriers to effective clinical translation in stroke research 
is the prevalent use of healthy, young animals in pre-clinical experiments.87, 88 
The majority of ischemic stroke patients are older than 65, and many of them  
have significant co-morbidities (atherosclerosis, hypertension, diabetes mellitus) 
that enhance ischemic stroke risk and contribute to poor post-stroke outcome.2 
To increase the chances that pre-clinical research will translate into effective 
clinical therapies, it is critical to incorporate aged animals into both mechanistic 
and therapeutic studies. In addition to the higher incidence of exacerbating co-
morbidities in aged patients, previous work from our lab and others shows that 
age itself has profound changes on both the brain and the peripheral response to 
cerebral ischemic injury.89-91 
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 Age impacts several aspects of ischemic stroke pathophysiology. Cerebral 
ischemia commonly results in two different injury territories; a dead ischemic core 
injury surrounded by penumbra, the brain tissue that is metabolically impaired but 
may still be salvageable.92 As we age, the likelihood of tissue rescue in the 
penumbra decreases, resulting in permanent loss of the majority of impaired 
tissue.93 Most importantly, the ability to recover function after ischemic stroke is 
decreased in older patients, indicating that advanced age may impair cerebral 
tissue repair and regeneration.94, 95  
In light of this, it is clear that the use of young animals to test therapeutics 
for ischemic stroke does not represent an ideal model, since therapies will be 
used to treat elderly patients with enhanced ischemic tissue damage and 
impaired regeneration potential. Ischemic stroke modeling in aged mice, which 
has recently been well-validated by our lab, may better replicate the physiological 
background of the typical ischemic stroke patient.96 
 
1.7 The Effects of Aging on Neutrophils 
Under normal conditions, neutrophils have short circulating half-lives, 
usually returning to the bone marrow, spleen, or liver for clearance within 24 
hours of their release.97 Recent evidence has shown that these exhausted 
neutrophils, typically identified by their low expression of CXCR2 and CXCR4, 
are also characterized by upregulation of the adhesion molecules ICAM-1, Mac-1 
and CD44.97-100 Perhaps driven by this increased ability to adhere, exhausted 
neutrophils are preferentially recruited into tissues following inflammatory 
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challenge. A study by Zhang et al. showed that neutrophils can become 
exhausted due to exposure to low-level inflammatory exposure in circulation.100 
In the same study, Zhang et al. found that exhausted neutrophils were capable 
forming higher levels of ROS and neutrophil extracellular traps (NETs).100  
As age is marked by increased chronic, low-level inflammation, it is 
possible that hyper-inflammatory, exhausted neutrophils are enriched in the 
circulation of aging individuals, significantly altering the inflammatory response to 
infection and injury in the aged. Several studies have shown higher levels of 
neutrophil infiltration into the lungs after pneumonia in older subjects, compared 
to younger subjects.101-103 In response to the same inflammatory stimuli, aged 
animals have higher levels of neutrophil-activating chemokines and a prolonged 
period of neutrophil infiltration into tissues than young animals.104-107 
Neutrophils from aged animals have been reported to produce higher 
levels of NETs and ROS compared to young neutrophils upon exposure to 
bacterial products.100 Some studies have also reported that the augmentation of 
ROS production in neutrophils with age, significantly impacting on injury 
outcome.108 Recent work has demonstrated that depletion of neutrophils protects 
old, but not young, mice from toxic-induced liver injury.109 However, the specific 
mechanism behind the enhanced pathogenicity of aged neutrophils in tissue 
injury remains uncharacterized.  
Another recent study has shown that neutrophil extracellular traps (NETs) 
increase in the circulation following acute ischemic stroke in patients.110 
Fascinatingly, this study also found that NETs were significantly increased stroke 
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patients over the age of 65 compared to levels found in younger stroke 
patients.110  
Similar aberrations in neutrophil function with aging have been described 
across a wide array of diseases, and it has been suggested that age-related 
changes in neutrophil function may be a significant driver of poorer outcomes in 
elderly patients.111 It is possible that age-related changes in the acute pro-
inflammatory capabilities of neutrophils can exacerbate secondary tissue injury 
after a major inflammatory event like ischemic stroke. 
 
1.8 Conclusions 
 Ischemic stroke affects millions of people every year, resulting in high 
mortality and contributing to a staggering loss in quality-of-life. We have outlined 
the detailed pathophysiology of ischemic stroke, including the pathways of 
primary initial injury and delayed secondary injury. Currently available stroke 
therapies, both of which target primary stroke injury and have a very narrow 
therapeutic window, were discussed.  Additionally, the detailed pathophysiology 
of ischemic stroke was reviewed, with particular attention to the role of excitatory 
neurotoxicity and post-stroke inflammation in secondary tissue injury. Within the 
scope of inflammation, neutrophils were identified as a likely culprit for 
inflammation-related damage after ischemic stroke. We presented several 
mechanisms of neutrophil-induced tissue damage that may be critical to stroke, 
including their ability produce high levels of reactive species (ROS and RNS). 
The role of aging as a major driver of ischemic stroke incidence and poor 
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outcome was also discussed. Finally, the very limited known data regarding the 
effect of host aging on neutrophil function was reviewed. 
 
1.9 Hypothesis and Research Goals 
 This dissertation investigates the effects of age on the inflammatory 
phenotype of neutrophils, and tests whether age alters the contribution of 
neutrophils to stroke pathology. Little is currently known about the effects of age 
on neutrophil function, and no studies have yet examined the relationship 
between age and the neutrophil response to stroke. The second chapter 
examines the relationship between age and stroke outcome in both human 
ischemic stroke patients and a mouse model of experimental stroke. The third 
chapter tests whether age intrinsically alters neutrophil function, or whether the 
neutrophil inflammatory response is dependent on the surrounding environment. 
In the fourth chapter, we investigate potential mediators of age-related changes 
in post-stroke neutrophil activation, mobilization and function in both mice and 
humans. In the fifth and final chapter, we utilize a neutrophil specific monoclonal 
antibody to deplete neutrophils after stroke onset, to examine the short and long-
term effects of anti-neutrophil depletion after ischemic stroke in both young and 
aged mice.  
 To summarize, I hypothesize that age enhances the pro-inflammatory 
phenotype of neutrophils after stroke, particularly reactive species generation, 
and contributes to the poor outcome seen in aged subjects. I further hypothesize 
that selective neutrophil depletion after stroke will (1) improve behavioral 
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outcome preferentially in aged animals and (2) permit examination of the in vivo 
pathogenic role of neutrophils in aged animals after ischemic stroke, an issue 
that has not been established to date.  
 
To test this hypothesis (Figure 3), I endeavored to: 
1. Examine the relationship between age, stroke and neutrophils  
a. In clinical ischemic stroke, utilizing demographic data and gene 
expression analysis 
b. In experimental ischemic stroke, by assessing the effects of age on 
neutrophil phenotype, neutrophil mobilization, and stroke outcome 
2. Determine if post-stroke anti-neutrophil depletion is differentially protective 
in aged mice by 
a. Examining the effect of anti-neutrophil depletion on infarct size and 
long-term brain tissue atrophy in young and aged mice 
b. Examining the effect of anti-neutrophil depletion on mortality and 
long-term functional outcome in young and aged mice 
3. Elucidate the effects of age on neutrophil inflammatory phenotype by 
a. Determining the effects of age on the quantity and quality of brain-
infiltrating neutrophils in young and aged animals after stroke  
b. Examining the influence of organism age on neutrophil cytokine 
and chemokine production, post-stroke neutrophil infiltration and 
the generation and detoxification of reactive species 
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Significance and Impact: This work will improve scientific knowledge regarding 
age effects on neutrophil function at baseline and after ischemic stroke. It will 
advance clinical practice by testing the utility of neutrophil depletion for the 
treatment of ischemic stroke in both young and aged animals, and may provide 
the basis for new efficacious therapies applicable to human ischemic stroke.  
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Figure 3. Graphical abstract illustrating dissertation specific aims. 
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Chapter II 
Aging increases stroke mortality and morbidity in patients and an 
experimental stroke model  
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2.1  Abstract 
Purpose: Aging is associated with poor outcome after ischemic stroke. Ischemic 
stroke results in the activation and recruitment of peripheral leukocytes, including 
neutrophils, to the brain. The purpose of our initial studies was to examine the 
relationship between aging, ischemic stroke outcome and the neutrophil 
response to stroke in (1) human stroke patients and (2) a mouse model of 
ischemic stroke.  
 
Experimental Design: Chart review of medical records and biological samples 
from ischemic stroke patients admitted to a major stroke center over a ten-year 
period was conducted. Demographic data, stroke severity, outcome data and lab 
values (absolute neutrophil and immature neutrophil counts) were obtained via 
retrospective chart review. For experimental studies, young (3 month) or aged 
(22-24 month) mice were subjected to middle cerebral artery occlusion (MCAO) 
or sham surgery. Mortality, weight loss, neurological deficit score, infarct size and 
hang-wire test were assessed. Flow cytometry was used to quantify neutrophil 
infiltration into the brain after experimental stroke in young and aged mice.  
 
Results: The average age of our stroke patient cohort was 69 years. Patients 
discharged to rehab/skilled facilities (high morbidity) or patients who died as a 
result of their stroke (mortality) were found to be significantly older than those 
who were discharged home (low morbidity). Ischemic stroke patients had 
significantly higher circulating neutrophil counts than control patients 24 hours 
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after symptom onset, and neutrophil count in stroke patients was positively 
associated with increasing stroke severity. Stroke severity was also positively 
associated with circulating counts of immature “band” neutrophils. In animal 
studies, young animals had significantly larger infarcts and higher levels of 
edema than aged animals. Aged animals showed significantly higher mortality, 
poorer weight recovery, poorer behavioral performance and more severe 
neurodeficit scores than young animals. 
 
Conclusions: Age significantly impacts ischemic stroke mortality and morbidity 
in human stroke patients and in an experimental mouse model. Circulating 
mature and immature neutrophil counts increase acutely in stroke patients in a 
severity-dependent manner. As seen in human patients, aged mice experienced 
higher mortality and poorer functional outcomes compared to young mice. Taken 
together, these results indicated that MCAO in aged mice is a good candidate 
model for the study of age-related neutrophil pathogenicity in ischemic stroke.   
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2.2 Introduction 
Stroke incidence increases dramatically with age, with the majority of 
strokes occurring in patients older than 65 years of age.2 The increased 
incidence of stroke during advanced age is associated with an age-related 
increase in stroke risk factors, including atrial fibrillation, diabetes, 
hyperlipidemia, coronary artery disease and hypertension.112, 113 Epidemiological 
studies show that aging is also associated with poorer functional outcome after 
stroke.3, 114, 115 Unfortunately, while thrombolytic and clot retrieval therapy can 
significantly improve stroke prognosis for patients, recent clinical research has 
shown that advanced age also increases the chances of poor outcome after IV 
tPA or intra-arterial therapy.116, 117 The uniquely high burden of stroke in the 
elderly, coupled with evidence that current therapeutics are less effective in aged 
patients, underscores the need for novel treatment modalities that can improve 
outcome in aged stroke patients.  
Recent work in the field of ischemic stroke has shown that aging has a 
significant impact on stroke outcome in mouse models, closely mirroring the 
patterns seen in ischemic stroke in humans.96 The impact of aging on brain 
physiology and injury is multifactorial, involving systemic changes throughout the 
body in addition to alterations in the central nervous system itself.118 
Inflammation has been increasingly recognized as a driver of age-related tissue 
dysfunction, a phenomenon known as “Inflammaging.”119 Inflammation is typically 
caused by tissue injury or pathogenic infection, and usually resolves once the 
pro-inflammatory stimulus has been eliminated.120 During conditions of long-term 
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or excessive inflammatory response, this resolution can fail, leading to a 
consistent state of non-productive, non-resolving inflammation. Inflammaging is 
characterized by a gradual increase in pro-inflammatory immune activation as an 
organism ages, which is believed to be largely driven by cells of the innate 
immune system, including neutrophils.121  
Neutrophils and neutrophil-associated inflammatory molecules have 
recently been found to predict both initial stroke risk and poor outcome after 
ischemic stroke. A study by Buck et al. found that early neutrophilia (within 24 
hours of stroke onset) in ischemic stroke patients was significantly predictive of 
larger infarct size.122 A higher neutrophil-to-lymphocyte ratio (NLR), a predictor of 
poor outcome in a variety of diseases, predicts poor short-term outcome, poor 
long-term outcome and the likelihood of hemorrhagic complications in ischemic 
stroke patients.123-125 Interestingly, studies have also shown that an elevated 
NLR in otherwise healthy patients is a significant independent risk factor for 
future ischemic stroke.126 In line with this data, neutrophils play a significant role 
in pathological processes that contribute to ischemic stroke risk, including 
atherosclerosis and thrombosis (clot formation).127-129 Circulating neutrophil 
counts increase within several hours of ischemic stroke onset.130 This increase 
likely results from increased neutrophil differentiation, augmented release of 
neutrophils from the bone marrow and spleen reservoirs, and suppression of 
neutrophil apoptosis.131 However, a significant gap in knowledge remains 
regarding the effects of age and inflammaging on neutrophil biology. Most 
importantly, we do not yet understand how age-related changes in the 
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destructive potential of neutrophils impact patients in conditions of excessive 
sterile inflammation, as seen in ischemic stroke. 
In order to best model the contribution of neutrophils to ischemic stroke 
pathology in patients, it is critical to realize that age may play a major role in 
ischemic stroke pathology for many patients. Despite success in animal models, 
clinical trials for ischemic stroke therapies have been largely unsuccessful. One 
critical barrier to effective therapeutic testing is the lack of pre-clinical testing in 
aged animals. To date, the vast majority of experimental stroke research is 
performed in young animals. However, ischemic stroke is largely a disease of the 
aging, which represents the single strongest independent risk factor for ischemic 
stroke.   
In this chapter, we aimed to (1) examine the relationship between 
ischemic stroke and neutrophil mobilization, (2) confirm the relationship between 
aging and increased ischemic stroke mortality and morbidity in human patients 
and (3) replicate the age-related increase in poor stroke outcome in a mouse 
model of ischemic stroke.  
 
 
 
 
 
 
 
30		
2.3 Materials and Methods 
Retrospective Chart Review: Chart review was conducted on patients admitted to 
Hartford Hospital (Hartford, CT) between 2005-2015. Hartford Hospital is a 868-
bed community-based teaching hospital certified as a JCO Comprehensive 
Stroke Center (CSC). Inclusion criteria were defined as ischemic stroke and 
transient ischemic attack (TIA) patients with known age, initial stroke severity and 
discharge disposition (n = 3635). TIA was defined as a brief and resolving acute 
onset focal neurological deficit. TIA patients were chosen as a control group as 
they have similar characteristics to stroke patients, including co-morbidities and 
age distribution. Ischemic stroke was defined as acute-onset focal neurological 
deficits with corresponding evidence of cerebral infarction on radiographic 
imaging (CT or MRI). Exclusion criteria were defined as ischemic stroke 
secondary to dissection, iatrogenic stroke or equivocal imaging. Human subject 
data for the demographic cohort are included in Table S1. The primary functional 
outcome was designated as initial stroke severity, as measured by National 
Institutes of Health Stroke Score Scale (NIHSS) on admission.  Statistical 
analysis: Linear regression analysis was used to examine the association 
between patient age and NIHSS admission severity (as a continuous variable). 
The secondary functional outcome was designated as discharge disposition, as a 
method of determining mortality (death or discharge to hospice) and morbidity 
(significant disability requiring significant rehabilitation or long-term care). 
Discharge disposition was categorized into three groups: Home with or without 
services (low morbidity), discharge to sub-acute or acute rehab (high morbidity), 
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or death/hospice discharge (death). The relationship between discharge 
disposition and age was examined via Kruskal-Wallis testing. 
 
Absolute Mature and Immature Neutrophil Counts: Patients from the 
demographic data cohort (n=3635) with available lab results were screened for 
this analysis. Exclusion criteria included active cancer, autoimmune disease, 
iatrogenic stroke and active immunosuppressive therapy. TIA control (n = 91) 
and ischemic stroke patients (n = 364) with available absolute mature neutrophil 
and immature band neutrophil counts within 24 hours of hospital admission were 
included in the analysis. Human subject data for the lab value cohort are 
summarized and included in Table S1. Statistical analysis: Differential neutrophil 
counts were analyzed by two-tailed Mann-Whitney test. The associations of 
neutrophil counts with age and stroke severity were analyzed by linear 
regression, followed by multivariate multiple regression to control for potential 
confounding variables.   
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Cohorts Stroke Outcome 
(Severity, Mortality and 
Morbidity) 
Absolute Neutrophil 
Count 
Age 
(Mean ± SD) 
69.3 ± 15.6 yr 75.7 ± 9.9 yr 
Sex (Female, %) 50.5 % 50.3 % 
N 3635 638 
 
Table S1. Patient Characteristics for Stroke Outcome and Neutrophil Count 
Studies. The average age, sex composition and n is given for the demographic 
outcome and absolute neutrophil count cohorts studied in Chapter 2. * SD = 
Standard Deviation; yr = year  
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Animal Information 
Young adult (3-4 mo) and aged (20-22 mo) C57BL/6J male mice were group-
housed in a specific pathogen facility on a 12h light/dark cycle. Aged animals 
were purchased at 12 months of age and continued to age in house for 8-10 
months.  Animals had access to water and chow ad libitum. All animal 
procedures were performed in accordance with NIH guidelines for the care and 
use of laboratory animals and approved by the University of Texas Health 
Science Center at Houston. 
 
Middle Cerebral Artery Occlusion (MCAO) Model of Ischemic Stroke 
Young (3-4 mo) and aged (22-24 mo) C567BL/6 mice were obtained from 
Jackson Laboratories or the National Institute of Aging. Animals were randomly 
assigned to MCAO or control groups. One surgeon performed all surgeries, 
which were randomized and distributed over days to reduce variation.  Mice were 
subjected to focal transient cerebral ischemia by 60 min of reversible MCA 
occlusion under Isofluorane anesthesia as previously described.132 In order to 
achieve equivalent levels of occlusion, 0.21 mm and 0.23 mm silicone coated 
sutures (Coating Length 2.5mm, Doccol) were used to occlude the MCA in young 
and aged mice, respectively.132 Rectal temperatures were maintained at 
approximately 37° C during surgical ischemia with an automated temperature 
control feedback system.  For verification of adequate ischemia, cerebral blood 
flow (CBF) was measured via Laser Doppler flow measurement (Moor 
Instruments), as previously described.133 
34		
Infarct Quantification 
Aged and young animals were sacrificed 24 hours post-stroke. Following 
sacrifice, brains were removed and flash frozen at -80°C. Brains were then sliced 
into 2mm coronal sections, and stained with 1.5% 2,3,5-triphentyltetrazolium 
(TTC, Sigma-Aldrich). Sections were fixed in 4% paraformaldehyde overnight 
before digital imaging and infarct measurement (Sigma Scan Pro5) by a blinded 
investigator as previously described.134 
 
Neurological Scores 
Neurological scores were recorded in mice at the time of reperfusion, and then 
once daily for seven days post-MCAO surgery. Neurological scoring was 
performed by an observer blinded to treatment group. In long-term outcome 
studies, neurological scoring was repeated at 7, 14, 21, 28 and 54 days. The 
scoring system is as follows: 0, no deficit; 1, forelimb weakness and turning of 
the torso to the ipsilateral side when held by tail; 2, circling towards the affected 
side; 3, unable to bear weight on affected side; and 4, no spontaneous locomotor 
activity or barrel rolling, as previously described.135 
 
Hanging Wire Test. In this test, mice utilize all four limbs to support their body 
weight on a wire-cage elevated 36 inches above a cage containing soft bedding. 
The time until the mouse fell was recorded, with an upper limit of 90 seconds. 
Mice unable to hang were excluded from the study. For trials involving aged 
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mice, the average hang time was corrected for weight, to adjust for the weight 
variability within the cohort.  
 
Sacrifice and Tissue Collection 
Mice were first anesthetized using 2,2,2- Tribromoethanol (Sigma-Aldrich, St. 
Louis, MO). Arterial blood was harvested via intracardiac puncutre into a 1ml 
syringe pre-coated with 1,000U heparin sulfate. For flow cytometric studies, 
animals were transcardially perfused with 60ml of sterile, cold PBS. The organs 
of interest (brain, lungs, femoral bone marrow and spleens) were subsequently 
collected and rinsed with cold, sterile PBS before processing.  
 
Flow Cytometry. Sham and stroke animals were anesthetized 24 hours after 
MCAO surgery and blood was obtained via intracardiac puncture, followed by 3 
rounds of RBC lysis with Tris-ammonium chloride (Stem Cell Technologies). 
Mice were transcardially perfused with 60 mL of sterile, cold PBS. Brains were 
collected and the olfactory bulbs, brainstem and cerebellum were removed. The 
cerebrum was divided into two hemispheres, and the ipsilateral (stroke) 
hemisphere was prepared for flow cytometry. Hemispheres were mechanically 
processed with a razor blade before enzymatic digestion in collagenase/dispase 
(Roche Diagnostics) and DNAse (Roche Diagnostics) at 37°C for 1 hour. 
Following incubation, the cells were filtered through a 70um filter screen, followed 
by leukocyte enrichment via density centrifugation (70%/30% Percoll, GE 
Lifesciences). Cells were washed twice with ice-cold PBS, followed by a 30 
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minute RT incubation with an amine-reactive viability stain (Ghost Dye 510, 
Tonbo Biosciences). Cells were spun down and re-suspended in FACS Buffer 
(PBS + 2% FBS) containing Fc Receptor Blocker CD16/32, 1:100 for 10 minutes 
at room temperature.  
 
Neutrophil Identification Flow Cytometry Panel: Following this blocking step, cells 
were re-suspended in the following cocktail of fluorescently conjugated 
antibodies: CD45-vf450 (Tonbo Biosciences), CD11b APC-Cy7 (Tonbo 
Biosciences), Ly6G-PeCy (Tonbo Biosciences) and Ly6C-PeCF594 (BD 
Biosciences) and incubated for 30 minutes at room temperature. After staining, 
cells were washed twice and re-suspended in 300ul FACS buffer for analysis on 
a Cytoflex S Flow Cytometer (Beckmann Coulter). Data files were analyzed using 
FlowJo (TreeStar). The representative gating strategy used is given in Figure 
S1. Positive and negative populations were defined using fluorescence minus 
one (FMO) controls.  
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Figure S1. Gating strategy for neutrophil identification (brain). Following 
gating for singlets and viability, immune cells are identified by their expression of 
the pan-immune cell marker CD45 and their expression of the myeloid lineage 
marker CD11b. Microglia, the resident immune cells of the brain, are identified as 
CD11b+/CD45Intermediate cells. Peripheral immune cells are identified as CD45High 
cells, with peripheral myeloid cells identified as CD11b+/ CD45High. Out of these 
peripheral myeloid cells, neutrophils are then defined as Ly6CIntermediate/Ly6GHigh. 
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2.4 Results 
Age influences stroke incidence, mortality and morbidity in human patients.  
Age has been implicated as a significant risk factor for both stroke incidence and 
poor stroke outcomes. To examine the relationship between age and stroke in 
our patient population, we conducted a retrospective chart review of patients 
admitted to a primary stroke care center over a 10-year period (Figure 4). We 
found that the average age of stroke patients in our demographic cohort was 69 
years (Figure 4A). Increasing age was significantly associated with greater initial 
stroke severity (Figure 4B, p<0.0001), as measured by the NIH Stroke Scale. 
Using discharge disposition as a measure of functional outcome, we found that 
patients with low morbidity at discharge were significantly younger (63.57 ± 15.01 
years) compared to patients in the high morbidity (72.15 ± 14.75 years) and 
mortality (79.2 ± 12.56 years) groups (p<0.0001, Figure 4C).  
 
Circulating neutrophil counts are increased in stroke patients in a severity-
dependent manner. To determine the relationship between ischemic stroke and 
neutrophil mobilization, we examined retrospective records of absolute mature 
and immature “band” neutrophil counts in ischemic stroke patients and TIA 
controls (Figure 5). Absolute mature neutrophil counts demonstrated that 
ischemic stroke patients have higher neutrophil counts (6049 ± 2952 
neutrophils/ul) compared to controls (4955 ± 1984 neutrophils/ul) 24 hours after 
symptom onset (p=0.0005, Figure 5A). Linear regression analysis within stroke 
patients demonstrated that neutrophil counts were significantly correlated with 
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increasing stroke severity (p<0.0001, Figure 5B). However, neutrophil counts in 
stroke patients were not significantly associated with patient age (p=0.80, Figure 
5C). As emergency granulopoiesis can be accompanied by an increased release 
of immature bone marrow neutrophils, or “bands”, from the bone marrow, we also 
assessed the effects of stroke on circulating band counts. There was a trend 
towards higher immature neutrophil counts in stroke patients (28.35 ± 29.09 
cells/ul) compared to controls (22.31 ± 16.54 cells/ul), although this difference did 
not reach statistical significance (p=0.13, Figure 5D). Within stroke patients, a 
significant correlation between stroke severity and increased circulating band 
count was observed (p=0.0018, Figure 5E). As with mature neutrophils, no 
significant effect of age on band counts within stroke patients was seen (p=0.49, 
Figure 5F). Multivariate multiple regression analysis was then performed, which 
confirmed that both mature (p=<0.0001) and immature (p=0.0006) circulating 
neutrophil counts increase with increasing stroke severity. No significant 
independent contribution of patient age or sex was seen. 
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Figure 4. Age, stroke incidence and stroke outcome of patients admitted to 
a major stroke center (n=3635). A. Distribution of age at stroke onset. B. 
Correlation of age vs. baseline stroke severity. C. Relationship between patient 
age and stroke outcome at discharge.  
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Figure 5. Association between injury severity (NIHSS deficit score) and 
circulating neutrophil counts within stroke patients. Blood from stroke 
patients or controls 24 hours after onset. A. Mature neutrophil counts in stroke 
(n=508) and TIA control patients (n=130). B. Mature neutrophil count and stroke 
severity, as measured by NIHSS on admission. C. Mature neutrophil counts and 
stroke patient age. D. Immature band counts in stroke and control patients. E. 
Immature band neutrophil count and stroke severity. F. Immature band neutrophil 
counts and stroke patient age. 
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Age exacerbates poor stroke outcome in a mouse model 
To examine the effect of age on stroke outcome in an animal model, we 
performed a 60 minute MCAO in young (3-4 mo) and aged (22-24 mo), with 
close monitoring of cerebral blood flow. In line with previous work in our lab, this 
model is capable of achieving similar degrees of cerebral ischemia in young and 
aged mice (Table 1).96 Aged mice weighed significantly more than young mice 
(p=0.0002), due in large part to excess fat deposition. Importantly, internal 
temperature during surgery was also equivalent between young and aged mice. 
Ischemic stroke histology data from young and aged animals is presented in 
Figure 6. Despite similar levels of cerebral blood flow reduction, young animals 
had significantly larger stroke sizes (Figure 6A, 6B) and a greater degree of 
edema (Figure 6C) than aged animals. 
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Age Weight (g) CBF Reduction (%)  Temperature (C) 
Young  
(3 months) 
26.24 ± 1.11 89.54 ± 2.70 36.60 ± 0.46 
Aged 
(20-22 months) 
34.68 ± 1.93 89.86 ± 1.76 36.82 ± 0.55 
Significance p=0.0002 n.s. n.s. 
 
Table 1. Ischemic stroke model parameters in young and aged mice. Young 
and aged mice were subjected to right MCAO stroke surgery. Weight (mean ± 
SD), cerebral blood flow (CBF) reduction (% of baseline, mean ± SD) and 
temperature during stroke (mean ± SD) are given. 
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Figure 6. Aged animals experience smaller infarcts and decreased edema 
following ischemic stroke. Young (3 month) and aged (24 month) mice were 
subjected to 60 minute MCAO. Brains were stained with TTC and infarct and 
edema were calculated (n=3/group) A. Representative TTC of 24 hour infarcts in 
young and aged mice. B. Infarct measurements of cortex, striatum and whole 
hemisphere. C. Edema quantification. *=p<0.05, **p<0.01 
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However, despite reduced infarct size, aged animals have significantly 
poorer outcomes following ischemic stroke compared to young animals (Figure 
7). Post-stroke mortality at 7 days was significantly higher in aged animals than 
in young animals (50% vs. 8.3%, p=0.03, Figure 7A). Although weight loss was 
initially higher in young animals (due to lower starting body weights), aged 
animals failed to begin weight recovery 4-5 days after stroke, resulting in 
significantly greater weight loss by day 7 post-stroke (p=0.005, Figure 7B). 
Neurodeficit scoring, an important measure of gross neurological dysfunction, 
was also significantly worse over the initial stroke recovery period (Figure 7C). In 
addition, hang-wire testing demonstrated significantly poorer strength recovery in 
aged animals 7 days post-stroke than in young animals (p=0.009, Figure 7D). 
These results are congruent with detailed behavioral testing done previously in 
our lab, demonstrating an overall poorer outcome for aged animals following 
ischemic stroke.96 
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Figure 7. Aged animals have poorer outcomes after ischemic stroke. Young 
(3 month) and aged (22-23 month) mice were subjected to 60 minute MCAO and 
followed for seven days. A. Mortality after stroke. B. Weight loss (as a 
percentage of baseline weight) over 7 days after stroke. C. Neurodeficit scores 
(NDS) over time. D. Hangwire test, corrected for weight and age-matched control 
performance. *=p<0.05, **p<0.01, ***=p<0.001, ****p<0.0001. n=12-14/grp for 
stroke mortality, weight loss and NDS, n=4-6 for hangwire testing. 
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Age does not alter neutrophil infiltration into the brain 24 hours after stroke. In 
order to confirm that neutrophils infiltrate the brain within 24 hours of experiment 
stroke, we performed flow cytometry on the ipsliteral brain hemisphere from 
young and aged stroke mice. Neutrophils were identified as 
CD45High/CD11b+/Ly6G+ cells, as demonstrated by the gating strategy shown in 
Figure S1. Stroke significantly increased neutrophils in the brain, both 
proportionally (p=0.0005) and by absolute counts (p=0.0007). However, no 
significant age difference in neutrophil infiltration into the stroke brain was 
observed.  
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Figure 8. Age does not alter neutrophil infiltration into the brain at 24 
hours. Flow cytometry was performed on the ipsliteral hemisphere of young and 
aged mice subjected to 60 minute MCAO sham or stroke surgery. Brain 
neutrophils (as a % of live, and absolute counts) are compared. ***=p<0.001, 
n=3-4/grp 
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2.5 Discussion 
 This study confirmed that the vast majority of patients in our cohort were 
over the age of 65, with a median age of 69 years. In addition, we corroborated 
previous reports of a positive association between patient age and increasing 
stroke severity. In addition, we also found that older stroke patients were more 
likely to die or require advanced rehabilitation compared to younger patients.  
Subsequently, our examination of a subset of patients with available 
absolute neutrophil counts within 24 hours of admission found that stroke 
patients have higher levels of circulating neutrophils compared to in-hospital, 
risk-factor matched controls. Additionally, we demonstrated that circulating 
neutrophil counts increase proportionally to initial stroke severity. Our data is in 
agreement with published work demonstrating that high levels of neutrophils in 
the circulation correlate with an increased in stroke severity and poorer functional 
outcomes.122, 136, 137  
Although our work was limited to circulating neutrophils, previous research 
in patients has shown that the timing of neutrophil accumulation into the brain 
occurs in concert with increases with circulating neutrophils (beginning within 6 
hours and peaking at 24 hours post-stroke), and that higher neutrophil 
accumulation in the brain is significantly correlated with poorer neurological 
outcome and larger infarct volumes.138 We found that post-stroke neutrophilia is 
positively associated with increased stroke severity, indicating that anti-neutrophil 
therapy may be best applied to patients with significant stroke volumes. 
Interestingly, we found no significant association between peripheral neutrophil 
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count after stroke and patient age. This suggests that age does not alter 
neutrophil number after stroke in the circulation, indicating that differences in 
neutrophil-mediated damage in aged stroke patients may instead be driven by 
differences in neutrophil phenotype.  
Our data confirms that age is linked to both increased stroke incidence 
and poorer functional outcome after stroke in human patients. These results 
highlight the importance of using aged models pre-clinical studies for stroke 
therapies, as the vast majority of the population requiring treatment will be aged.  
Next, we performed experimental animal studies in young and aged mice 
to confirm that age-related increases in ischemic stroke mortality and morbidity 
can be replicated in an animal model. In line with previous work done by our lab, 
young male mice had larger infarcts and greater levels of cerebral edema than 
aged male mice, despite similar reductions in cerebral blood flow. Using flow 
cytometry, we found that stroke results in significant neutrophil infiltration into the 
brains of both young and aged animals 24 hours after injury onset. No difference 
was seen in absolute neutrophil infiltration between young and aged animals. 
This suggests that, as in human patients, age does not significantly increase the 
magnitude of neutrophil mobilization recruitment at 24 hours.  
Despite a larger initial injury size in young mice, aged male mice were 
found to have significantly poorer outcomes after ischemic stroke, including 
increased neurodeficit scores, higher mortality, poorer behavioral outcomes and 
an inability to regain weight. These drastic age differences in outcome illustrate 
the importance of examining (1) the driving mechanisms behind poor recovery in 
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aged mice after brain injury and (2) the testing of future therapeutics in animals 
across the lifespan.  
In Chapter 2, we have shown that age significant increases the mortality 
and morbidity of ischemic stroke in both human patients and in an experimental 
mouse model (Figure 9). However, whether age impacts the inflammatory 
function of neutrophils remains unknown. In Chapter 3, we will examine the 
effects of age on the inflammatory functions of neutrophils in vivo and ex vivo.  
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Figure 9. Graphical abstract illustrating findings from Chapter 2 
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Chapter III 
Age augments neutrophil reactive species generation in a 
location-specific manner 
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3.1  Abstract 
Purpose: Initial studies performed in ischemic stroke patients and a mouse 
model of ischemic stroke demonstrated that age exacerbates neurological 
deficits, mortality and functional loss. In this series of experiments, we examined 
the effects of age on neutrophil cytokine secretion and neutrophil reactive 
species production, two major potential causes of neutrophil-mediated tissue 
damage.  
 
Experimental Design: Serum levels of inflammatory cytokines in neutrophils 
from young and aged mice was measured via multiplex ELISA. The production of 
reactive species in the blood and bone marrow neutrophils of young and aged 
mice was analyzed by flow cytometry. Protein levels of reactive-species 
generating and neutralizing enzymes in isolated young and aged neutrophils 
were measured by Western Blot. Finally, we examined the reactive species 
content of bone marrow resident neutrophils and brain-infiltrating neutrophils in 
young and aged animals after ischemic stroke. 
 
Results: Our results indicated that age does not significantly affect cytokine and 
chemokine production from naïve, bone marrow neutrophils. Similarly, age did 
not effect the generation of reactive species or protein levels of pro-oxidative 
(NOX2, iNOS)/anti-oxidative enzymes (Catalase, SOD1). However, circulating 
neutrophils from aged mice were found to be larger, more granular and more 
likely to produce reactive species than young neutrophils after ex vivo 
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stimulation. In addition, brain-infiltrating neutrophils in aged animals had 
significantly higher neutrophil reactive species content than those in young 
animals after ischemic stroke. 
 
Conclusions: We determined that, while cytokine production and reactive 
species production is similar in young and aged bone-marrow neutrophils, 
circulating and brain-infiltrating neutrophils from aged animals produce higher 
levels of reactive species than young neutrophils. These results suggest that 
age-related alterations in neutrophil function are not cell-intrinsic, but may instead 
result from signals present in the systemic circulation and injured tissue of aged 
animals.   
 
 
 
 
 
 
 
 
 
 
 
 
56		
3.2 Introduction 
Although neutrophils have traditionally been considered as effector 
“soldiers” of the immune system, recent work has shown that neutrophils are also 
capable of producing a wide variety of inflammatory cytokines and chemokines. 
These neutrophil-derived factors, which are capable of reacting with a wide 
variety of innate and adaptive immune cells, can play a significant role in the 
regulation of the immune system.139 In this Chapter, we will measure the ability of 
neutrophils from young and aged animals to produce cytokines and chemokines 
at baseline and after inflammatory stimulus.  
In addition to inflammatory cytokines, neutrophils are also capable of 
producing large amounts of reactive species upon stimulation. An increase in 
reactive species generation has been implicated in many age-related diseases 
and inflammatory conditions.140 In the majority of cells, free radicals are 
necessary byproducts of cellular metabolism and respiration, and also play a key 
role in intracellular signaling. Phagocytic immune cells, including neutrophils, can 
also harness the production of free radicals into an anti-microbial “oxidative 
burst.”141 The primary source of reactive oxygen species in neutrophils is NADPH 
oxidase (NOX2), which is capable of generating superoxide anions without 
mitochondrial involvement.142 Reactive nitrogen species are also produced in 
large quantities within neutrophils by the enzyme inducible nitric oxide synthase 
(iNOS). Previous studies have reported that neutrophil-specific iNOS is a major 
driver of poor outcome after ischemic stroke in mice.65 Superoxide dismutase is 
the primary enzyme responsible for catalyzing the reaction of superoxide anions 
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(O2-) into hydrogen peroxide (H2O2), which is then further detoxified by catalase 
into H2O and O2. While the oxidative burst is beneficial under conditions of 
infection, if left unchecked, excessive build-up of reactive species within 
neutrophils has been implicated in the exacerbation of tissue damage.143 
In this chapter, we tested potential characteristics of aged neutrophils 
believed to contribute to their heightened pathogenicity in aged mice after 
ischemic stroke. To that end, we examined whether age significantly altered (1) 
neutrophil cytokine production and (2) neutrophil reactive species production. 
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3.3 Materials and Methods 
Neutrophil Isolation.  
For experiments requiring isolated neutrophils, mice were anesthetized and 
transcardially perfused with 60ml ice-cold PBS prior to cervical dislocation. All 
long bones of the forelimbs and hindlimbs were dissected out, cleaned of muscle 
and fat and washed in 70% ethanol. Bones were then crushed in a small mortar 
and pestle containing 5ml of Hanks Balanced Salt Solution (HBSS) without 
calcium and magnesium, supplemented with 2% heat-inactivated fetal bovine 
serum, in order to remove the bone marrow. The resulting bone marrow 
homogenate was filtered through a 40um cell strainer into a 50ml falcon tube, 
then washed twice with HBSS + 2% FBS. The bone marrow cells were then re-
suspended in 1ml room temperature HBSS and layered onto a gradient made of 
Histopaque-1.077 (3ml) and Histopaque-1.119 (Sigma). Cells were centrifuged at 
500g for 30 minutes at room temperature with the brake off, mononuclear cells at 
the HBSS/1.077 interface were removed and discarded, and neutrophils were 
collected at the 1.077/1.119 interface. Cells were then washed twice with HBSS 
+ 2% FBS and re-suspended in 500ul HBSS before negative magnetic isolation 
via the Stem Cell Mouse Neutrophil Isolation Kit (Stem Cell Technologies). 
 
Cytokine Analysis. Isolated neutrophils were incubated with 0, 50 or 200 nM PMA 
at 37°C for 45 minutes. After stimulation, the supernatant was collected and 
frozen down at -80°C until use. Samples were thawed and chemokine levels 
were measured in plasma using the Bio-Plex Pro Mouse Chemokine Assay (Bio-
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Rad), on a Bio Plex 200 Luminex System. Cytokine and chemokines with 
detectable supernatant levels were then analyzed by multiple T-testing, with 
correction for multiple comparisons, in order to determine the effects of PMA 
stimulation on neutrophil chemokine production.  
 
Single-Cell Arterial Blood and Brain Suspension Preparation 
Arterial blood was subjected to three rounds of 10 minute RBC lysis on ice using 
Tris-ammonium Chloride (Stem Cell Technologies, Cambridge, MA) at 9:1, 4:1 
and 4:1 stringencies. The remaining white blood cells were washed twice with 
500ul of cold PBS, then placed in 1ml of supplemented RPMI (Life Technologies) 
containing L-glutamate, 2.5% HEPES Buffer, 1X Pen-Strep, 5% heat-inactivated 
FBS until staining. Spleens and bone marrow were removed, mechanically 
disrupted and filtered through a 70um filter screen, followed by 1 round of RBC 
lysis with Tris-ammonium chloride. Brains were split into ischemic and non-
ischemic hemispheres, then placed into a petri dish containing 5ml of 
supplemented RPMI and mechanically diced with a razor blade. Brains were then 
chemically digested with collagenase/dispase (1mg/ml, Roche Diagnostics) and 
DNAse (10 mg/ml, Roche Diagnostics for 45 minutes at 37°C. After filtration 
through a 70um filter, the brain homogenate was applied to a 30%/70% Percoll 
gradient. After centrifugation, brain leukocytes were harvested from the gradient 
interface and washed with 10ml of supplemented RPMI, then re-suspended in 
1ml of flow cytometry buffer (FACS Buffer: 1X Sterile PBS, 2% Heat-Inactivated 
Calf Serum) for further staining.  
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In Vivo ROS Assay. Single-cell brain and bone marrow suspensions were 
washed twice in 1X sterile, cold PBS, followed by viability staining with Ghost 
Dye 510 (Tonbo Biosciences) for 30 minutes in the dark at room temperature. 
Cells were centrifuged at 500g for 5 minutes at 4°C, the supernatant was 
discarded and the pelleted cells were re-suspended in 100ul of 1:100 FC 
Receptor Block (Tonbo Biosciences) for 10 minutes at room temperature. Cells 
were then stained with following surface antibodies: CD45-vf450, CD11b-APC-
Cy7, Ly6G-Pe-Cy7, Ly6C-APC (Tonbo Biosciences) for 30 minutes at room 
temperature, protected from light. Following surface staining, samples were 
incubated with dihydrorhodamine 1,2,3 (DHR) and 200 nM PMA for 45 minutes 
at 37°C according to the manufacturer’s instructions (Neutrophil Monocyte 
Respiratory Burst Assay Kit, Cayman Chemical), then washed and analyzed 
immediately for rhodamine fluorescence on a Beckmann Coulter Cytoflex S Flow 
Cytometer. Data was analyzed using FlowJo (TreeStar).  
 
Ex Vivo ROS Assay.  
Neutrophils isolated as described above were then counted and diluted to a 
concentration of 1x10^6 cells/ml. Cells were stained with surface markers 
mentioned above (CD45, CD11b, Ly6G, Ly6C). Following surface staining, 
dihydrorhodamine 1,2,3 dye (DHR), PMA and incubation buffer were used 
according to manufacturer’s instructions (Neutrophil Monocyte Respiratory Burst 
Assay Kit, Cayman Chemical). 100ul of cells were taken and incubated with DHR 
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and various concentrations of PMA (0, 25, 50, 100, 200, 400 nM PMA) for 45 
minutes at 37°C. Flow cytometry was used to identify neutrophils, and measure 
median fluorescence intensity of the DHR signaling per cell.  
 
Western Blotting. 
Neutrophils were isolated as described above, counted and diluted to a 
concentration of 1 x 10^6 cells/ml. Cells were washed twice with ice cold PBS 
and immediately placed on ice.  Cell pellets were then lysed by the addition of 
100ul of lysis buffer: 1X TBS, 0.1% NP-40, Protease Cocktail (Sigma), 
COMPLETE Protease Inhibitors (Roche) and PHOS-Stop (Roche). Cells were 
incubated on ice for 15 minutes, followed by centrifugation at 12,000g for 20 
minutes at 4°C. The supernatant was removed and 4X loading buffer (Bio-Rad) 
containing 2-mercaptoethanol was added before boiling at 100°C for 5 minutes. 
Samples were stored at -80°C until use. For western blotting, samples were run 
on Criterion Gels (Bio-Rad, 12%) for 1 hour at 90V, followed by transfer to PVDF 
membrane (3 hours at 60V). Membranes were blocked with 5% BSA in TBST, 
followed by incubation with one of the following primary antibodies overnight at 
4°C: iNOS (Rabbit anti-mouse, Abcam) at 1ug/ml, SOD1 (Rabbit anti-mouse, 
Abcam) at 1:2000, NOX2 (Rabbit anti-mouse, Abcam) at 1:500 and Catalase 
(Rabbit anti-mouse, Abcam) at 1:500 in TBST. After washing three times in 
TBST, membranes were incubated with HRP Conjugated Goat Anti-Rabbit 
secondary antibody (Vector, 1:20,000 in TBST) for 1 hour at room temperature. 
After washing three times in TBST, cells were incubated for 5 minutes with ECL 
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Western Blotting Substrate (Thermo Fisher) before visualization on a Bio-Rad 
ChemiDoc XRS system. HRP-conjugated anti-mouse B-actin (Sigma) was used 
as a loading control. Data were analyzed by two-way ANOVA, followed by 
Sidak’s multiple comparisons test.  
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3.4 Results 
In the following experiments, we sought to examine the effects of age on the 
ability of neutrophils to produce (1) inflammatory cytokines and chemokines and 
(2) reactive oxygen species.  
 
Age Does Not Affect the Production of Neutrophil-Derived Cytokines and 
Chemokines. Neutrophils were cultured for one hour with no stimulation, 50 nM 
of PMA or 200 nM PMA. The supernatant was then collected and 
cytokine/chemokine production was measured by multiplex ELISA. Out of 32 
valid analytes, neutrophils were found to secrete detectable amounts of 22 
cytokines and chemokines. Of these, 11 were found to be significantly 
upregulated by exposure to the inflammatory activator PMA, after adjustment for 
multiple testing (Table 2). PMA treatment significantly increased neutrophil 
secretion of the inflammatory cytokines IL-6 and TNFa, as well as a significant 
upregulation in the secretion of several lymphocyte chemokines (CCL25, 
CXCL13, CXCL10, CCL17). Importantly, neutrophils also showed a dramatic 
upregulation of monocyte and neutrophil-associated chemokines, including 
CCL4, CCL3, CXCL2 and CXCL12.  
Samples were then separate based on the age of the donor mouse, in 
order to allow the examination of age effects on neutrophil chemokine secretion. 
(Figure 10). No significant differences were seen in inflammatory cytokine or 
chemokine production in young and aged neutrophils across all stimulation 
conditions.  
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Table 2. Neutrophil production of inflammatory chemokines and cytokines 
Analyte	(pg/ml)	 0	nM	PMA		 50	nM	PMA	 q	value	 FC	
CXCL2	 214.3	±	2.31	 248.60	±	64.76	 <0.0001	 32.92	
CCL3	 104.3	±	1.27	 122.30	±	43.18	 <0.0001	 26.75	
CXCL12	 373.5	±	20.07	 323.40	±	112.11	 0.0001	 10.66	
CCL4	 38.41	±	3.54	 69.87	±	23.80	 0.0001	 3.44	
IL-6	 2.97	±	0.42	 5.59	±	1.16	 <0.0001	 1.59	
TNF-a	 14.65	±	2.60	 18.90	±	2.72	 <0.0001	 1.39	
CCL17	 2.89	±	0.76	 4.93	±	0.83	 0.0002	 0.97	
CXCL13	 199.80	±	31.42	 256.30	±	32.92	 0.002	 0.62	
CCL24	 131.60	±	19.62	 101.90	±	33.79	 n.s.	 0.57	
CCL5	 15.14	±	3.60	 12.78	±	5.96	 n.s.	 0.55	
CXCL10	 83.23	±	11.10	 101.30	±	9.58	 0.0001	 0.51	
CCL25	 174.40	±	36.75	 231.00	±	43.93	 0.03	 0.36	
CCL20	 6.73	±	1.26	 6.85	±	1.19	 n.s.	 0.28	
CX3CL1	 19.86	±	4.51	 26.15	±	2.10	 0.04	 0.26	
CCL1	 2.03	±	0.50	 2.67	±	0.79	 n.s.	 0.25	
CCL27	 306.40	±	77.50	 413.30	±	45.75	 n.s.	 0.18	
CCL7	 1.32	±	0.49	 1.83	±	0.28	 n.s.	 0.05	
IFN-y	 4.90	±	2.20	 6.02	±	0.99	 n.s.	 0.01	
IL-10		 38.60	±	17.62	 63.20	±	14.52	 n.s.	 -0.01	
CXCL11	 33.46	±	17.88		 41.88	±	9.40	 n.s.	 -0.08	
IL-16	 86.37	±	25.70	 77.87	±	45.03	 n.s.	 -0.21	
IL-1B	 30.04	±	17.16	 28.39	±	9.24	 n.s.	 -0.3	
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Figure 10. Heat map of differentially expressed cytokines and chemokines 
in young and aged cultured neutrophils. Neutrophils were isolated from 
murine bone marrow and stimulated for 1 hour with 0, 50 or 200 nM PMA. 
Chemokine and cytokine production was measured in the culture supernatant by 
multiplex ELISA.  
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Age does not affect levels of pro-oxidative or anti-oxidative enzymes in naïve 
neutrophils. As studies have shown that age enhances reactive species 
generation in human neutrophils, we next wanted to examine whether age 
affected the levels of pro-oxidative and anti-oxidative enzymes in murine 
neutrophils. We saw no effect of age on the levels of the reactive-producing 
enzymes NADPH Oxdiase (NOX2, gp91phox subunit) or inducible nitric oxidase 
synthase (iNOS) in isolated bone marrow neutrophils (Figure 11).  Similarly, no 
significant influence of age was seen on the reactive species neutralizing 
enzymes catalase or superoxide dismutase 1 (SOD1) (Figure 12). 
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Figure 11. Age does not alter levels of reactive species generating enzymes 
in bone marrow neutrophils.  Western blot analysis of neutrophils isolated and 
purified from the bone marrow of young and aged mice. Primary antibodies 
against NOX2 and iNOS were used. Data is presented as a ratio to B-actin 
loading control.  
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Figure 12. Age does not alter levels of reactive species scavenging 
enzymes in bone marrow neutrophils.  Western blot analysis of neutrophils 
isolated and purified from the bone marrow of young and aged mice. Primary 
antibodies against catalase and SOD1 were used. Data is presented as a ratio to 
B-actin loading control.  
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Age does not affect granularity, size or reactive species content in bone marrow 
neutrophils. As protein levels of enzymes do not directly correlate with enzyme 
activity, we also measured the production of intracellular reactive species via flow 
cytometry using dihydrorhodamine 1,2,3, a fluorescent indicator of reactive 
oxygen and nitrogen species. Bone marrow neutrophils were stimulated PMA, a 
powerful inflammatory activator, over a range of concentrations (0-200 nM) for 45 
minutes before analysis by flow cytometry (Figure 13).  No significant difference 
in granularity (Figure 13A), size (Figure 13B) or intracellular reactive species 
content (Figure 13D) between young and aged neutrophils at any PMA 
concentration. A slight increase in the % of reactive species positive neutrophils 
in young animals compared to aged animals was seen after stimulation with 200 
nM PMA (Figure 13C).  
 
 
 
 
 
 
 
 
 
 
 
70		
 
Figure 13. Age does not affect neutrophil granularity, size or reactive 
species content in the bone marrow. Neutrophils from young (3 month) and 
aged (22-24 month) mice were isolated from the bone marrow of both hind 
femurs. Cells were exposed to increasing concentrations of PMA for 45 minutes, 
than analyzed for granularity (A), size (B), reactive species positivity (C) and 
intracellular reactive species content (D). **=p<0.01, n=4-5/grp. 
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Age augments neutrophil activation and reactive production in circulating 
neutrophils. Although we observed no significant differences in reactive species 
producing/neutralizing enzymes or intracellular reactive species generation in 
bone marrow neutrophils, we hypothesized that aged differences in reactive 
species generation may exist in circulating neutrophils. Circulating murine 
neutrophils from naïve mice were exposed to 200 nM PMA or PBS control 
(Figure 14), followed by flow cytometry to measure side scatter (SSC), forward 
scatter (FSC) and intracellular reactive species production (DHR). We found that 
neutrophils from aged animals had significantly higher SSC than those from 
young animals (Figure 14A), indicating a higher level of granularity/activation. In 
addition, aged neutrophils were also found to have significantly greater FSC 
compared to young neutrophils, indicating an increase in overall neutrophil size 
(Figure 14B). Measurement of intracellular reactive species production showed 
that a significantly higher percentage of aged neutrophils were positive for 
intracellular reactive species after PMA stimulation (Figure 14C), with a trend 
towards increased reactive species content (Figure 14D) compared to young.  
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Figure 14.  Age enhances markers of neutrophil activation and ROS 
production in circulating neutrophils. Neutrophils from the blood of naïve 
young and aged mice were stained for neutrophil identification markers 
(CD45+/CD11b+/Ly6CInt/Ly6GHi), followed by incubation with or without PMA in 
the presence of 1,2,3 DHR to measure changes in (A) neutrophil granularity 
(SSC) and (B) neutrophil size (FSC), as well as the percentage of ROS positive 
neutrophils (C) and intracellular ROS production (D). *p=<.05, **p=<.01, 
***p=<0.001, ****p=<0.0001 
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Brain neutrophils from aged animals have higher levels of intracellular reactive 
species. Finally, we sought to measure the levels of intracellular reactive species 
in brain-infiltrating and bone marrow neutrophils after stroke (Figure 15). Aged 
brain neutrophils had significantly higher granularity (Figure 15A) and were 
significantly larger (Figure 15B) compared to young neutrophils. No age 
difference in the percentage of neutrophils producing reactive species after 
stroke was seen in brain or bone marrow neutrophils (Figure 15C). In line with 
the results seen previously in circulating neutrophils, brain-infiltrating neutrophils 
from aged mice after stroke had significantly higher levels of intracellular reactive 
species compared to those from young animals (Figure 15D). Importantly, in 
agreement with our results from naïve mouse bone marrow, no age difference in 
intracellular ROS content was seen in bone marrow from mice after stroke, 
indicating that this age-related enhanced oxidative phenotype may be restricted 
to neutrophils that have exited the bone marrow. 
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Figure 15. Age augments ROS production in brain-infiltrating neutrophils. 
24 hours after stroke, young (3 month) and aged (24 month) mice were 
sacrificed, and brains and bone marrow were prepared for flow cytometry. 
Intracellular ROS production by neutrophils in the bone marrow and brains of 
young and aged stroke mice at 24 hours by dihydrorhodamine (DHR) assay. The 
effects of age on (A) neutrophil granularity (SSC) and (B) neutrophil size (FSC), 
as well as the percentage of ROS positive neutrophils (C) and intracellular ROS 
production (D) were assessed. **p=<.01, ***p=<0.001 
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3.5 Discussion 
The overall goal of these experiments was to determine whether age 
significantly alters pro-inflammatory cytokine or reactive species production in 
neutrophils. Furthermore, we wished to determine whether age-related changes 
in reactive species production were cell-intrinsic (inherently present in all mature 
neutrophils) or dependent on neutrophil mobilization and egress into the systemic 
circulation. Neutrophils were found to produce a variety of inflammatory cytokines 
and chemokines after inflammatory stimulation, in agreement with existing 
literature.144 However, no significant effects of age on inflammatory cytokine or 
chemokine production from bone marrow neutrophils were seen.  
Under inflammatory conditions, high intracellular levels of neutrophil 
reactive species can be released into the extracellular space in an uncontrolled 
manner.145 This “spilling” of internal ROS has been implicated in the 
pathogenesis of many diseases, including ischemic stroke.146 Next, we examined 
whether neutrophils from aged mice produce higher levels of reactive species 
than young mice. We found no differences in the levels of reactive species-
generating or detoxifying enzymes in bone marrow neutrophils from young and 
aged animals. In line with these results, no effect of age was seen on intracellular 
reactive species levels in bone marrow neutrophils after ex vivo stimulation with 
PMA or in vivo stimulation (ischemic stroke). However, age was found to 
significantly increase the activation and percentage of reactive species producing 
neutrophils in circulation.  
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We then performed flow cytometry on brains from young and aged mice at 
24 hours after stroke. Despite no significant difference in the number of brain-
infiltrating neutrophils, neutrophils from aged animals were found to have 
significantly higher intracellular reactive content than neutrophils found in the 
brains of young animals. This phenomenon appeared to be specific to the 
activated neutrophils within the brain, as a similar age difference was not seen in 
neutrophils taken from the bone marrow.  
The main weakness of this study was our inability to test the causative 
role of age differences in neutrophil-derived ROS in the context of ischemic 
stroke. While previous studies have shown that both iNOS and NADPH oxidase 
contribute to ischemic stroke pathology in young animals, these enzymes are 
expressed in both immune and non-immune cells, preventing a conclusive 
connection between neutrophil-derived ROS and stroke outcome.65, 147 
Unfortunately, as mature neutrophils are terminally differentiated and easily 
activated, they are exceedingly resistant to knockdown via SiRNA or gene 
delivery.148 Further experiments utilizing knockout under the control of the newly 
discovered, neutrophil-specific MCL-1 gene promoter, may represent a promising 
future tool for the study of different oxidative enzymes in age-related neutrophil 
reactive species generation.86  
In summary, age was not found to affect the ability of bone marrow 
derived neutrophils to generate cytokines or reactive species after stimulation. 
Further experiments demonstrated that there is an age-dependent increase in 
neutrophil reactive species in circulating, but not bone marrow, neutrophils after 
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ex vivo inflammatory challenge. Importantly, the same increased oxidative 
phenomenon was seen in vivo after ischemic stroke, with brain-infiltrating 
neutrophils from aged mice expressing significantly higher levels of intracellular 
ROS than those from young animals. These results indicate that age-related 
increases in neutrophil oxidative potential may represent one potential 
mechanism for the poor outcomes seen in aged animals after stroke (Figure 16). 
Interestingly, this enhanced oxidative phenotype was only seen in circulating and 
brain-infiltrating neutrophils, indicating that age-related differences may result 
from exposure of circulating neutrophils to systemic factors. In Chapter 4, we will 
examine the effects of age and stroke on (1) circulating neutrophil phenotype and 
(2) levels of neutrophil-activating factors in circulation.  
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Figure 16. Graphical abstract of findings from Chapter 3. 
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Chapter IV 
Aging alters circulating neutrophil phenotype and levels of neutrophil-
activating factors after stroke  
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Purpose: Previous work determined that the enhanced reactive species 
production in aged neutrophils was not intrinsic to bone marrow neutrophils, 
indicating that systemic, circulating factors may play a role in age-related 
alterations in neutrophil functions. In light of this, we examined the effects of 
aging and stroke on circulating neutrophil phenotype and the levels of neutrophil-
activating factors in mice and humans.  
 
Experimental Design: Young (3 month) or aged (22-24 month) mice were 
subjected to middle cerebral artery occlusion (MCAO) or sham surgery. 
Measurements of neutrophil-activating cytokines (IL-6, CXCL1, G-CSF) and flow 
cytometry of blood, bone marrow, lungs and spleen was performed in order to 
determine how stroke and age affect neutrophil proportions throughout multiple 
organ systems. For human studies, serum cytokine measurements of IL-8 and 
IL-6 were performed in a cohort of stroke patients and matched controls with 
available bio-samples. Whole blood obtained from a subset of stroke patients 
was obtained and analyzed by whole transcriptome RNA-sequencing, with sub-
analysis of differentially upregulated gene pathways in younger vs. older stroke 
patients.  
 
Results: Overall, aged animals had significantly higher proportions of neutrophils 
in the blood, bone marrow, spleen and lungs. Neutrophils from aged animals had 
significantly reduced surface levels of the bone-marrow homing receptor CXCR4 
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compared to young neutrophils. Additionally, the post-stroke levels of the CXCR4 
ligand CXCL12 was significantly lower in aged animals after stroke. Finally, aged 
stroke animals were found to have significantly higher levels of the neutrophil 
activating cytokines IL-6, CXCL1 and G-CSF compared their young counterparts. 
In human stroke patients, serum cytokine levels of IL-6 and IL-8 were increased 
in stroke patients compared to controls, and post-stroke levels of these cytokines 
were positively associated with increasing patient age. Stroke induced the 
overexpression of neutrophil degranulation pathway genes in human patients, 
with a greater upregulation seen in aged stroke patients compared to younger 
stroke patients.  
 
Conclusions: Neutrophil proportions in the bone marrow, blood, spleen and 
lungs were higher in aged animals compared to those seen in young animals 
both at baseline and after ischemic stroke. This neutrophilia may be driven by the 
(1) increased levels of neutrophil-activating cytokines (IL-6, CXCL1, G-CSF and 
(2) the reduction in factors required for the proper clearance of neutrophils 
(CD44, CXCR4, CXCL12) seen in aged animals. In human stroke patients, we 
found a similar augmentative effect of stroke and age on the levels of Il-6 and IL-
8 (the human homolog of CXCL1), as well as an increase in genes involved in 
neutrophil degranulation in older stroke patients. This data indicates the 
increased magnitude of neutrophil inflammatory activation may be partly driven 
by an increase in circulating levels neutrophil-activating cytokines and 
chemokines in aged organisms.  
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4.2  Introduction 
Our previous work has shown that aging has a significant impact on stroke 
outcome in mouse models and human patients.96 The impact of aging on brain 
physiology and injury is multifactorial, involving systemic changes throughout the 
body in addition to alterations in the central nervous system itself.118 
Inflammation has been increasingly recognized as a significant driver of age-
related tissue dysfunction, a phenomenon known as “Inflammaging.”119 
Inflammaging is characterized by a gradual increase in pro-inflammatory immune 
activation as an organism ages, which is believed to be largely driven by cells of 
the innate immune system.121 Inflammation is typically caused by tissue injury or 
pathogenic infection, and usually resolves once the pro-inflammatory stimulus 
has been eliminated.120 During conditions of long-term or excessive inflammatory 
response, this resolution can fail, leading to a consistent state of non-productive, 
non-resolving inflammation.  
 Neutrophils are believed to exist in three states; quiescent, primed and 
activated.149 Quiescent neutrophils are those described above, which mature and 
move quickly through the circulation before returning to the bone marrow, if no 
activating stimuli are encountered in the periphery. During highly inflammatory 
conditions like injury or infection, neutrophils in circulation will encounter a variety 
of activating substances, including cytokines (Il-6, IL-8, G-CSF), complement 
factors and DAMPs, that will stimulate them to undergo oxidative burst, NET 
extrusion and degranulation.149 These activated neutrophils can then override 
83		
their natural programmed apoptosis and upregulate adhesion molecules on their 
surface, enhancing their ability to survive and extravasate into nearby inflamed 
tissue.150   
 The primed state represents an intermediate phenotypic phase between 
quiescent and activated, in which no increased oxidative activity is seen. 
Nonetheless, stimulation of primed cells results in 10x greater responses than 
those seen in quiescent cells.151 It has been suggested that neutrophils can cycle 
between quiescent and primed phases, allowing for robust inflammatory 
responses when needed, but limiting unnecessary neutrophil activation and 
degranulation in order to prevent collateral tissue damage.152 However, in 
conditions of chronic inflammation, the majority of circulating neutrophils will 
become inappropriately primed by the pro-inflammatory systemic milieu, giving 
them the potential to produce unwarranted and excessive tissue damage upon 
activation by infection or injury.153  
 When neutrophils are released from healthy bone marrow, they typically 
have a very short life span, with an average half-life of eight hours.68, 154, 155 As 
they circulate, neutrophils become exposed to a variety of low-level inflammatory 
stimuli, facilitating their shift from quiescent to primed.100 However, in states of 
relatively low systemic inflammation, these neutrophils begin to upregulate the 
surface CXCR4 receptor, which is involved in the return of neutrophils to the 
bone marrow and their apoptosis and clearance by macrophages.156 CD44, a 
ligand for E-selectin, also plays a role in the regular clearance of apoptotic, pro-
inflammatory neutrophils from circulation.157 
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 As organisms age, the systemic milieu shifts towards a pro-inflammatory 
environment, characterized by higher circulating levels of inflammatory cytokines 
such as IL-6.158 These factors, in addition to others, are capable of neutrophil 
priming and activation. As neutrophils have been shown to have an extraordinary 
and uniquely plastic phenotype, even short-term exposure to low-grade systemic 
inflammaging could be enough to significantly increase the potential for 
bystander host tissue damage upon injury-induced activation.159 
In this chapter, we examined the effect of age on (1) the organ distribution 
of neutrophils after stroke, (2) the surface phenotype of circulating neutrophils 
and (3) the circulating levels of neutrophil-activating cytokines in mice and 
humans after ischemic stroke.  
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3.3 Materials and Methods 
Neutrophil Surface Marker Phenotyping Flow Cytometry Panel: Blood was drawn 
from naïve young (3 month) and aged (22 month) mice via cardiac puncture and 
prepared as above. In addition to neutrophil quantification markers described 
above and in Figure S1, cells were also stained with an antibody cocktail 
containing four neutrophil surface markers: CD62L-FITC (Biolegend), CXCR4 
PerCP-Cy5.5 (Biolegend), CXCR2 PE (Biolegend) and CD44 PE-Dazzle 
(Biolegend) and incubated for 30 minutes at RT. After staining, cells were 
washed twice and re-suspended in 300ul FACS buffer for analysis on a Cytoflex 
S Flow Cytometer (Beckmann Coulter). Data was analyzed as described above.  
 
Serum & Plasma Cytokine Measurements  
Blood was drawn from anesthetized young and aged mice 24 hours after sham 
or stroke surgery via cardiac puncture. Blood for plasma preparation was drawn 
with a 1ml syringe/18g needle pre-coated with heparin (1000U), and collected 
into a tube containing 50ul of diluted (200U) heparin. The tube was gently 
inverted several times at room temperature before centrifugation at 4°C for 20 
minutes at 15,000 RPM. After centrifugation, the top layer of plasma was 
removed and stored at -80°C until testing. Chemokine levels were measured in 
plasma using the Bio-Plex Pro Mouse Chemokine Assay (Bio-Rad), on a Bio 
Plex 200 Luminex System. Two neutrophil chemokines were selected for further 
analysis (CXCL2 and CXCL12) by two-way ANOVA.  
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In order to best match the serum cytokine data from our human cohort, we 
elected to analyze levels of circulating inflammatory cytokines in serum. Blood for 
serum preparation was drawn into a clean 1ml syringe/18g needle into a tube 
without anti-coagulant, and allowed to clot at room temperature for two hours 
before centrifugation and removal of the serum supernatant. Serum was stored 
at -80°C until analysis. The levels of IL-6, CXCL1 (the two cytokines identified to 
change with age in stroke patients) and G-CSF (an important neutrophil growth 
factor) were assessed using the Bio-Plex Pro Mouse Cytokine Assay (Bio-Rad), 
on a Bio-Plex 200 Luminex System. Data was analyzed by two-way ANOVA.   
 
Human Serum Cytokine Measurements: 
Sample and demographic data collection was conducted at a 868-bed 
community based teaching hospital certified as a JCO Comprehensive Stroke 
Center (CSC). Blood was drawn from patients (n = 143) and controls (n=17) at 
24 ± 6 hours after symptom onset in tubes containing no anticoagulant. Human 
subject data for the serum cohort are located in Table S2. Blood was allowed to 
clot at room temperature for two hours before centrifugation and removal of the 
top layer of serum supernatant. Serum samples were stored at -80°C until use. 
Levels of IL-6 and IL-8 were measured in patient serum samples (n=160) by Bio 
Plex Pro Human Cytokine Assay (BioRad). All human sample collection was 
approved by the Institutional Review Board at Hartford Hospital.  
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Statistical Analysis: Differences in two selected serum cytokines (IL-6 and IL-8) 
between stroke and control patients were analyzed by Mann-Whitney test. Linear 
regression was then used to examine the univariate relationship between stroke 
patient age and serum levels of IL-6 and IL-8 at 24 hours. Finally, multivariate 
multiple regression analysis to assess the independent relationship between 
stroke patient age and serum IL-6 and IL-8 after adjustment for stroke severity 
and patient gender as potential confounding variables.  
 
Human Peripheral RNA Collection and Sequencing:  
Blood was drawn from patients with middle cerebral artery strokes, cardioembolic 
subtype (n = 16) at 24 ± 6 hours after symptom onset. Additional human subject 
data for the RNA-sequencing cohort is given in Table S3. Patients were stratified 
into older (>75 yrs) and younger (<75 years), and selected to create an 
approximate age and stroke severity match between the two groups. For control 
studies, blood was also drawn from asymptomatic controls (n=8) recruited at the 
University of Connecticut Health Center. All human sample collection was 
approved by the Institutional Review Board at Hartford Hospital and the 
University of Connecticut Health Center. Blood samples were drawn into 
PAXGene tubes (Qiagen) and stored at -80C until use. Samples were thawed 
and RNA was extracted by PAXGene blood RNA kit (Qiagen). cDNA libraries 
were generated from isolated RNA, followed by RNA-sequencing analysis at the 
Center for Genome Innovation (UConn, Storrs, CT) via the Illumina NextSeq 500 
Sequencer. The subsequent FASTQ files were genome aligned (Top Hat 
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Alignment, Illumina Inc) and analyzed for differential expression (Cufflinks 
Assembly & DE, Illumina Inc). Differentially expressed genes underwent FDR 
correction (Bejamani-Hochberg) prior to gene pathway analysis (Reactome). 
Results reported in this manuscript are limited to pathways with significant q 
values following FDR correction, with >2 gene family members represented.   
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TIA Control 
Patients 
 
     Ischemic Stroke Patients 
Age  
(Mean ± SD) 
64.5 ± 11.13 yr 69.3 ± 14.7 yr 
Sex (Female, %) 25.0% 47.0% 
N 17 143 
 
Table S2. Patient Characteristics for Serum Cytokine (Il-6 and IL-8) 
Measurement Studies. The average age, sex composition and n is given for the 
patients included in the serum cytokine analysis in Chapter 4. * SD = Standard 
Deviation; yr = year  
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 Stroke Patients (<75 yr)  Stroke Patients (>75 yr)  p-value 
N 9 7  
Age  
(Mean ± SD) 
85 ± 5.3 yr 64 ± 6.8 yr <0.0001 
Stroke Severity 11 ± 5.2 9.4 ± 5.2 n.s. 
MCA Stroke 100% 100% n.s. 
Co-morbidities 
Hypertension 
Heart Disease 
Hyperlipidemia 
Diabetes 
 
89 % 
50 % 
77 % 
42 % 
 
100 % 
57 % 
71 % 
22 % 
 
n.s. 
n.s. 
n.s. 
n.s. 
 
Table S3. Patient Characteristics for RNA-Sequencing Age Analysis. 
Demographic table demonstrating differences between our younger (<75 years) 
and elderly (>75 years) stroke patients. There are no significant differences in 
stroke severity, stroke location or associated co-morbidities between the cohorts.  
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3.4 Results 
Age differences in neutrophil proportions are seen in multiple organs after 
ischemic stroke. Although stroke has been shown to exacerbate the release of 
neutrophils from the bone marrow, no published data has yet examined the 
effects of aging on stroke-induced neutrophilia. Flow cytometry was conducted in 
blood, lungs, bone marrow and spleens from young and aged mice 24 hours 
after stroke or sham surgery (Figure 17). By two-way ANOVA, a significant 
overall decrease in neutrophil proportions in the bone marrow was seen 
(p=0.0039), characteristic of the robust post-stroke release of bone marrow 
neutrophils into the circulation (Figure 17A). Interestingly, a significant overall 
effect of age was also seen (p=<0.0001), with aged animals displaying relative 
increase in neutrophils within the bone marrow compared to young animals 
under both sham (p=0.0005) and stroke (p=0.0062) conditions. 
As expected, stroke resulted in an overall increase in neutrophil 
proportions within peripheral blood (p=<0.0001), with aged animals exhibiting 
higher neutrophilia (p=0.0127) than young animals (Figure 17B). However, 
despite a significantly higher proportion of neutrophils in the peripheral blood of 
aged sham animals compared to young (p=0.05), there was no significant 
difference in neutrophil proportions in the blood of young and aged stroke 
animals. Stroke increased the percentage of neutrophils in the lungs after 
ischemic stroke in both age groups (Figure 17C, p=<0.0001), with an overall 
neutrophilic shift seen with aging (p=<0.0004) due to higher neutrophil ratios in 
both aged sham (p=0.017) and stroke (p=0.0054) animals compared to their 
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young counterparts (Figure 17C).  In the spleen, there were also significantly 
higher neutrophil proportions after ischemic stroke (p=0.008), with a significant 
effect of age (p=0.0097) driven by a significantly higher proportion of neutrophils 
in the spleens of aged stroke mice (p=0.015) compared to young stroke mice 
(Figure 17D).  
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Figure 17. Age and stroke significantly alter neutrophil proportions across 
multiple organs. Neutrophils in the bone marrow, blood, lungs and spleen of 
young (3 month) or aged (22 month) mice were identified by flow cytometry 24 
hours after stroke or sham surgery. Neutrophils were identified as 
CD45+/CD11b+/Ly6CInt/Ly6GHi cells. *=p<0.05, **p<0.01, ***=p<0.001, 
****p<0.0001. n=3-6/grp. 
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Age reduces the expression of receptors required for bone marrow homing and 
clearance of circulating neutrophils.   In light of the age-related neutrophilia seen 
across multiple organ systems in Figure 8, we sought to examine whether age 
differences in markers of neutrophil trafficking existed in naïve mice (Figure 18).  
CXCR2 and CXCR4 have been shown to control the release of naïve neutrophils 
from the bone marrow and their return as exhausted apoptotic neutrophils 
respectively. Although there was no significant age difference in CXCR2 
expression in blood (Figure 18A), we found that a greater proportion of 
neutrophils from young animals expressed the bone-marrow homing CXCR4 
receptor (p=0.0003), and that young CXCR4+ neutrophils also had a higher 
expression of the receptor per cell (p=0.0021) than aged neutrophils (Figure 
18B).  
Flow cytometry of blood from naïve young and aged mice revealed that, 
while all circulating neutrophils express CD44, those from young mice expressed 
significantly higher levels of CD44 on their cell surface (Figure 18C, p=0.0008). 
No significant age differences in L-selectin, another cell adhesion molecule found 
on neutrophils, were observed (Figure 18D).  
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Figure 18. Age reduces expression of receptors required for proper 
neutrophil clearance. Neutrophils isolated from the blood of naïve young and 
aged mice were stained for neutrophil identification markers 
(CD45+/CD11b+/Ly6CInt/Ly6GHi), surface chemokine receptors (CXCR2, CXCR4) 
and adhesion molecules (L-selectin, CD44). **p=<.01, ***p=<.001 
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Figure 19. Age alters levels of the bone marrow homing chemokine 
CXCL12. Plasma was taken from young (3 month) or aged (22 month) old 
animals 24 hours following sham or stroke surgery. N=7-12 animals/group. 
CXCL12 and CXCL2 were measured via multiplex. Two-way ANOVA was 
performed, followed by individual T-Tests with Sidak’s correction. *p=≤.05, 
**p=<0.01. A schematic figure of the differential roles of CXCL12 and CXCL2 in 
circulating neutrophil homeostasis.  
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Age alters levels of the bone marrow homing chemokine CXCL12. As our 
previous work showed that neutrophils from aged mice express significantly 
lower levels of CXCR4, the receptor for the bone marrow-homing chemokine 
CXCL12, we next sought to examine the effects of age and stroke on circulating 
levels of this chemokine at 24 hours after stroke (Figure 19). In addition, we also 
measured levels of CXCL2, the bone marrow release chemokine responsible for 
binding CXCR2 and coordinating the release of neutrophils into the blood. A 
significant interaction effect of age and stroke was seen in CXCL12 levels 
(p<0.0001), with aged animals showing higher levels of CXCL12 (p=0.05) under 
sham conditions, but significantly lower levels of CXCL12 (p=0.006) than young 
animals after ischemic stroke. No significant effects of age or stroke were seen 
on levels of CXCL2. A schematic figure illustrating the roles of CXCL2 and 
CXCL12, and their cognate receptors CXCR2 and CXCR4, is shown (Figure 19).  
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Aged mice display altered circulating levels of neutrophil-associated cytokines 
after stroke. We then examined serum cytokine levels in young and aged mice 
24 hours after ischemic stroke or sham surgery. Levels of IL-6 (a powerful 
neutrophil-activating cytokine), CXCL1 (the primary neutrophil chemoattractant, 
and G-CSF (a cytokine which stimulates neutrophil production and bone marrow 
release) (Figure 20). By two-way ANOVA, there was a significant stroke effect 
on serum IL-6 levels (p = <0.0001) in both young and aged animals. A significant 
age effect (p = <0.0001) and an interaction effect of age/stroke (p=0.0005) was 
also seen, driven by the augmented increase in IL-6 after stroke in aged animals 
(p=<0.0001) compared to young animals. Serum levels of CXCL1, a potent 
neutrophil chemokine, were found to be significantly elevated in aged animals 
over young animals, regardless of sham or stroke status (p=0.05). By two-way 
ANOVA, there was a significant increase in G-CSF in stroke animals (p=0.02). 
Although the overall effect of age on G-CSF levels was not significant (p=0.06), 
there was a significant interaction effect of age and stroke on serum G-CSF 
(p=0.05), driven by the significantly higher increase in G-CSF levels in aged 
animals after stroke compared to young animals (p=.02).    
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Figure 20. Aged mice display altered circulating levels of neutrophil-
associated cytokines after stroke. Levels of the neutrophil-associated 
cytokines IL-6, CXCL1 and G-CSF in serum from young (3 month) and aged (20-
22 month) animals 24 hours after sham or stroke surgery. *p≤0.05, **p=<0.01, 
***p=<0.001, ****p=<0.0001. Data was analyzed by two-way ANOVA, followed by 
Sidak’s multiple comparisons test. n=3/4 mice per group. 
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Stroke patient age influences circulating levels of neutrophil-associated 
cytokines. In light of our results in mice, we then examined the serum levels of IL-
6, IL-8 (the human homolog of murine CXCL1) and G-CSF in the serum of 
human ischemic stroke patients and controls at 24 hours (Figure 21). As levels 
of G-CSF were undetectable in >50% of patients, these results were not 
analyzed. Stroke patients were found to have significantly higher levels of serum 
IL-6 (stroke: 6.26 ± 9.23 pg/ml, control: 1.96 ± 3.77 pg/ml, p=0.0014) and IL-8 
(stroke: 7.27 ± 36.53 pg/ml, control: 3.15 ± 2.47 pg/ml, p=0.0017) compared to 
controls (Figure 21A). Looking within the stroke patient population, we found that 
increased age was significantly positively associated with higher levels of IL-6  
(p=0.015) and IL-8 (p<0.0001) in serum 24 hours after stroke (Figure 21B). In 
order to assess the effects of age independently from other confounding 
variables (initial stroke severity and patient sex), we performed multivariate 
multiple regression analysis (Figure 21C). After adjustment, age remained a 
significant independent predictor of higher IL-8 levels after ischemic stroke 
(p=0.0008).  
 
Neutrophil degranulation genes are significantly upregulated in older stroke 
patients. A homogeneous subset of ischemic stroke patients (n=16) with large 
middle cerebral artery strokes of cardioembolic origin was selected for RNA-
sequencing. Differential gene analysis was examined between all stroke patients 
(n=16) and controls (n=8), and between older stroke patients (>75, n=7) and 
younger stroke patients (<75, n=9). This age cut-off was selected based on 
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previous work in ischemic stroke demonstrating significantly poorer outcome in 
elderly patients, defined as >75 years of age.160-163 These patient subgroups 
were carefully matched for stroke severity, stroke location and known stroke co-
morbidities (Table S3). The top upregulated pathways between stroke and 
control patients were neutrophil degranulation, immune system and interleukin 
signaling (Table 3). In a sub-analysis of the stroke patients, older people were 
found to have significant upregulation of genes in both the interferon signaling 
and neutrophil degranulation pathways (Table 3).  
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Figure 21. Relationship between stroke patient age and serum levels of 
neutrophil-activating cytokines. Levels of the inflammatory cytokines IL-6 and 
IL-8 were measured in serum from stroke patients or transient ischemic attack 
controls 24 hours after stroke onset. A. Comparison of control (n=17) and stroke 
(n=143) cytokine levels. B. Linear correlation between ischemic stroke patient 
age and serum cytokine levels. C. Multivariate analysis examining the 
relationship between patient sex, age, stroke severity and cytokine level. 
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Table 3. Effects of stroke and age on circulating gene expression  
All Stroke Patients vs. Controls  p-value FDR 
1. Neutrophil degranulation 
 
 
<0.0001 <0.0001 
2. Immune System 
 
<0.0001 0.0002 
3. Interleukin Signaling 
 
<0.0001 0.0049 
Older Strokes (>75 yr) vs. Younger Strokes (<75 yr)   
1. Interferon Signaling: 
2. Neutrophil degranulation 
3. O2/CO2 Exchange in Erythrocytes 
   0.0015 
   0.0024 
   0.0026 
  0.0392 
0.0392 
  0.0392 
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4.5   Discussion 
Age was found to increase neutrophil proportions in the bone marrow, 
blood, lung and spleen at baseline in aged animals compared to young. 
Additionally, stroke-induced neutrophil proportions in these compartments were 
higher in aged animals than in young animals. Taken together, this data 
demonstrates that aging results in a neutrophil-skewing of white blood cells 
levels throughout the body, an effect that is exacerbated in injury. It is possible 
that this neutrophilia is driven by higher levels baseline of circulating 
inflammatory cytokines, or “Inflammaging” in aged animals. Neutrophils who 
receive consistent low levels of inflammatory activation may resist normal 
apoptosis and become primed, allowing them to circulate throughout the body for 
longer and augmenting neutrophil pro-inflammatory reactivity after injury.  
To examine whether aging was associated with an increase in circulating 
cytokines, we assessed the effect of age and ischemic stroke on serum cytokine 
levels in mice 24 hours after ischemic injury.  We found that aging significantly 
increased the circulating levels of CXCL1 in both sham and stroke animals. 
Furthermore, we saw an interactive effect of age and stroke on levels of G-CSF 
and IL-6 levels, with an augmented stroke-induced increase in these circulating 
cytokines in aged animals compared to young animals. These results show that 
levels of neutrophil-associated inflammatory cytokines and chemokines are 
significantly elevated in aged animals at baseline and after ischemic stroke, 
suggesting one potential mechanism for the age-related increase in neutrophil 
proportions seen throughout the body.  
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Delayed return of neutrophils to the bone marrow may also contribute to 
age-associated neutrophilia. To that end, we examined the surface phenotype of 
peripheral blood neutrophils from young and aged mice and found that aging is 
associated with a significant decrease in CXCR4 and CD44 expression on the 
surface of neutrophils. As these surface molecules are responsible for the return 
of circulating neutrophils at the end of their life span, these surface changes may 
indicate that tired, “primed” neutrophils persist inappropriately in the circulation of 
aged animals, enabling faster reactivity and exacerbated tissue damage after 
infection or injury.  
Taken together, these results suggest that age is associated with an 
increase in overall neutrophilia and an increase in neutrophil-activating cytokines 
and chemokines, which is exacerbated after ischemic stroke. Neutrophils from 
aged animals show an increase in activation both at baseline and after 
inflammatory stimulus, but also display a down-regulation of receptors necessary 
for clearance of primed cells.  
To support our findings in mice, we then examined the association of 
ischemic stroke with levels of IL-6 and IL-8 in human patients. Both IL-6 and IL-8 
have previously been reported to increase in ischemic stroke patients.164, 165 IL-8, 
also known as CXCL8, is the major driver of directed neutrophil chemotaxis in 
humans and has been shown to promote neutrophil degranulation and 
respiratory burst.166, 167 IL-6 is a pro-inflammatory cytokine that has previously 
been shown to accelerate the release of neutrophils from the bone marrow, and 
to enhance neutrophil migration towards IL-8.168, 169 In agreement with previous 
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reports, we found that IL-6 and IL-8 levels were significantly higher in stroke 
patients compared to controls 24 hours after symptom onset. Within stroke 
patients, IL-6 and IL-8 were found to be positively associated with increasing 
stroke severity. Our data also demonstrates that aging is significantly correlated 
with higher levels of IL-6 and IL-8 in stroke patients. As injury severity and patient 
sex have both been reported to impact the magnitude of the post-injury 
inflammatory response,170, 171 we performed multivariate multiple adjustment 
analysis to adjust for sex and stroke severity. Even after the adjustment, aging 
remained an independent predictor of higher IL-8 levels in ischemic stroke 
patients.  
We then wished to investigate whether age altered neutrophil function in 
human stroke patients. Unfortunately, as neutrophils cannot be preserved long-
term, neutrophil-specific functional analysis with our stored biobank samples was 
not possible. However, using whole-blood RNA-sequencing, we were able to 
demonstrate that the neutrophil degranulation pathway was the most significantly 
upregulated gene expression pathway in a highly homogenous population of 
ischemic stroke patients compared to controls. When we divided the ischemic 
stroke patient cohort into those <75 years of age and those >75 years of age 
(age cut-off determined as described in Section 4.3), we found that the neutrophil 
degranulation pathway was significantly more upregulated in older stroke 
patients. Our results indicate that, while neutrophil numbers in circulation do 
significantly differ based on age, the reactivity of neutrophils in stroke patients 
may be enhanced in aged subjects. This data is supported by work done in 
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healthy adult humans, which found that neutrophils from healthy aged individuals 
show greater degranulation responses to inflammatory stimulation when 
compared to those from young individuals, characterized by an increase in 
primary granule mobilization, higher neutrophil proteinase activity and increased 
neutrophil elastase degradation products.172  
There are several limitations in these studies that must be addressed. Due 
to the age-skewing of stroke patient demographics in our cohort, we were limited 
to comparing the effects of age on neutrophil count in a range of patients from 60 
to 100 years of age. However, we feel that these results in human patients 
provided a solid platform from which to base a more specific investigation in an 
animal model of ischemic stroke.  
Nevertheless, our RNA-sequencing results were also limited to the same 
age range, but still showed a significant difference in gene expression between 
patients from 60-75 years of age and patients > 75 years of age. As non-genetic 
stroke in young patients is relatively rare67, these parameters may be best 
studied in animal models where surgical induction of stroke can be performed in 
both young and aged animals. 
An additional weakness in our study is the use of RNA-sequencing in 
whole blood, rather than western blot or neutrophil-specific mRNA analysis. 
Unfortunately, the ex vivo study of neutrophils in human patients is complex, as 
neutrophils do not survive cryopreservation or extensive culture and must be 
examined fresh.173 Given the timely and cost-prohibitive process of neutrophil 
isolation and the requirement for immediate preparation, we elected to use whole 
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blood in our studies. Since white blood cells account for the vast majority of 
mRNA in whole blood and neutrophils represent the largest source of RNA in 
whole blood preparations from ischemic stroke patients174,  
We have shown that age is associated both with poorer stroke outcome in 
mice, as well as in humans. Our data demonstrates that aged animals exhibit an 
increase in neutrophil proportions in several organs, perhaps driven by an age-
related increase in neutrophil-activating factors (Il-6, CXCL1, G-CSF) and a 
decrease in bone-marrow homing factors (CD44, CXCR4/CXCL12) in aged 
animals. In addition, we have shown that age is associated with increased levels 
of neutrophil-activating cytokines (IL-6 and IL-8) and increased neutrophil 
degranulation gene expression in stroke patients (Figure 22).   
 However, it still remains unknown whether these age-related changes are 
a driver of the poor stroke outcomes seen in aging mice. In the next Chapter, we 
will utilize a highly specific method of neutrophil depletion to further examine 
whether neutrophils are a causative factor in poor stroke outcome in the aged.   
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Figure 22. Graphical abstract of findings from Chapter 4.  
* indicates results also seen in human ischemic stroke patients.  
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Chapter V 
Post-stroke neutrophil depletion improves outcome after stroke 
in aged mice. 
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5.1  Abstract 
Purpose: Despite success in experimental animal models of ischemic stroke, all 
clinical trials of anti-neutrophil therapies to date have been unsuccessful. All 
previously examined anti-neutrophil therapies were relatively non-specific and 
were tested only in young animals, potentially contributing to their failure to 
effectively translate to improved outcomes in patients. Administration of a 
monoclonal antibody to Ly6G can specifically and significantly deplete 
neutrophils in mice. We utilized this antibody to examine whether age influences 
the pathological role of neutrophils in ischemic stroke, with examination of 
mortality rates, behavioral outcomes and long-term tissue atrophy. To assess the 
potential influence of sex on therapeutic efficacy, these studies were then 
repeated in aged female animals. Follow-up studies investigating the effects of 
anti-Ly6G on acute infarct size, hemorrhagic transformation and infection risk 
secondary to neutrophil depletion were also performed.  
 
Experimental Design: After dose optimization, anti-Ly6G antibody was given to 
young and aged male mice at 4, 24 and 72 hours after stroke. In Cohort 1, the 
effects of neutrophil depletion on sub-acute mortality were examined. Cohort 2 
examined long-term treatment effects, including functional and histological 
outcomes, out to two months after stroke. Finally, we determined the effect of 
neutrophil depletion on acute brain tissue injury (72 hours), hemorrhagic 
transformation and post-stroke infection risk in aged mice. 
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Results: Anti-Ly6G treatment conferred no benefit to young mice, but 
significantly improved short-term mortality and behavioral recovery in aged mice. 
Anti-Ly6G treatment was also found to be effective in improving behavioral 
recovery in female mice. These improved outcomes were independent of 
changes in long-term tissue atrophy. Further studies found that, while neutrophil 
depletion did not affect peak infarct size or significantly increase bacterial burden 
in the lungs at 72 hours, animals receiving anti-Ly6G showed significantly less 
secondary hemorrhage into tissue compared to control.  
 
Conclusions: Post-stroke anti-Ly6G treatment significantly improved outcomes 
in aged animals only, independent of peak infarct size or long-term tissue 
atrophy. A similar protective effect of neutrophil depletion was seen in aged 
females and aged males. Neutrophil depletion therapy did not significantly alter 
peak infarct size at 3 days post-stroke, but was found to significantly reduce the 
degree of hemorrhage in treated animals at 7 days post-stroke. Neutrophil 
depletion did not significantly alter post-stroke temperature, nor was it found to 
impair bacterial clearance.  
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5.2 Introduction.  
 Work by our lab has previously shown that bone marrow transplantation 
between young and aged significantly alters post-stroke outcome (Ritzel et al, in 
submission). Aged mice receiving marrow from younger mice had significantly 
improved outcomes and decreased neutrophil infiltration into the brain, compared 
to aged mice receiving transplants from aged-matched controls. Young animals 
transplanted with bone marrow from aged mice were seen to have higher rates of 
hemorrhagic transformation, a serious and damaging complication of ischemic 
stroke typically seen more often in aged subjects.  
As neutrophils have been previously implicated in the process of 
hemorrhagic transformation after stroke, we hypothesized that aged neutrophils 
may represent the major detrimental factor in aged bone marrow. However, as 
bone marrow is comprised of many different cells types, a more specific method 
of neutrophil inhibition was required to test this hypothesis.  
To date, the question of whether neutrophil infiltration into the brain is a 
contributing factor or a consequence of stroke pathology remains largely 
unknown.175 Many strategies have been employed to interfere with neutrophil 
activation, adhesion and transmigration, with promising animal results, yet none 
of the therapies that made it to clinical trials have shown any positive effect on 
patient outcome.84, 176-194   
One significant flaw in all anti-neutrophil clinical trials to date is that, 
despite their intended purpose, none of the drugs chosen were cell-type specific. 
Enlimomab, which increased infections and hemorrhagic transformation in 
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patients, is an antibody against ICAM-1, an adhesion molecule expressed on all 
immune cells and some endothelial cells.176 Due to this non-specificity, the 
increased hemorrhage and infection risk may have resulted from endothelial 
dysfunction or the global impairment of all immune cells. Similarly, the clinical 
trials of UK-276 (anti-CD11b/CD18) and LeukArrest (CD-18) targeted a 
component of a surface receptor found on all cells of myeloid origin.178, 179 These 
cells include monocytes/microglia/macrophages, which have been shown to be 
integral to tissue healing and functional repair after ischemic stroke.24, 195  
In addition to maximizing the specificity of anti-neutrophil therapies, it is 
critical to realize that neutrophils themselves play several important roles after 
injury, including prevention against infection. One tested anti-neutrophil 
therapeutic, Enlimomab, was found to increase the likelihood of serious 
infections in stroke patients.176, 179 As infection is a major risk factor for poor 
outcome after ischemic stroke, it is critical to understand and test the effects of 
anti-neutrophil therapeutics on infection risk in patients.196, 197  
The timing of anti-neutrophil therapy is also important. Given the narrow 
therapeutic window of currently available stroke therapies, it is critical to find 
therapies that can benefit stroke patients beyond three hours. Yet many tested 
stroke therapies, including anti-neutrophil focused studies, involve depletion or 
inhibition before or at the time of stroke onset, significantly reducing the clinical 
translatability of the results. In line with this, genetic deletion of neutrophils via 
disruption in the MCL-1 gene, are not an ideal method of testing neutrophils as a 
therapeutic target in stroke.86   
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In light of these results, we elected to choose a method that would allow 
us to 1. Deplete neutrophils after stroke (non-genetic based therapy), 2. Achieve 
high specificity (to reduce suppression of other, potentially beneficial cell types) 
and 3. yield short-term reductions in circulating neutrophils (to limit the risk of 
prolonged neutropenia and infection).  We selected Anti-Ly6G (clone 1A8), a 
monoclonal antibody against the Ly6G receptor on neutrophils, as an ideal 
choice for these studies. Anti-Ly6G is highly specific for neutrophils, targeting 
them for removal from the circulation and subsequent degradation by 
macrophages.198, 199  
In these studies, we sought to examine whether neutrophils were a driving 
factor in poor outcomes in aged mice after stroke. We hypothesized that anti-
Ly6G would specifically and reversibly deplete neutrophils after ischemic stroke, 
and that anti-Ly6G therapy would confer greater benefit to aged animals than 
young animals.  
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5.3 Materials and Methods 
MCAO Stroke Surgery. Animal care and surgery was performed as described in 
Chapter 3. In Cohort 1, aged male and female mice were 24 months of age. In 
Cohort 2, slightly younger mice were utilized (Cohort 2) to equalize mortality 
rates and prevent mortality bias in long-term functional and histological studies.  
 
Cresyl violet atrophy quantification 
In cresyl violet cohorts, transcardial perfusion with cold, heparinized PBS was 
followed by 4% paraformaldehyde. Brains were collected, fixed in 4% cold 
paraformaldehyde for 24 hours, then placed into a 30% sucrose solution to 
dehydrate. Following dehydration, brains were frozen and sliced into 30-um 
slices on a freezing microtome, with every eighth slice mounted and stained with 
cresyl violet for the evaluation of brain atrophy. Digital images were taken and 
infarct volumes were measured via computer software (Sigma Scan Pro5) as 
previously described.134 
 
Drug Administration. Mice were randomized to receive either 500ug anti-Ly6G 
monoclonal antibody (Clone 1A8, BioXCell) or isotype control antibody (Clone 
2A3, BioXCell) intraperitoneally (I.P.) at 4, 24 and 48 hours after sham or 
ischemic stroke surgery. For the dose determination experiment, an additional 
group of mice receiving 200ug of anti-Ly6G antibody was added. Investigators 
were blinded to treatment until the conclusion of the studies (at 7 days, or 2 
months). 
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Neutrophil Depletion Confirmation. Flow cytometry was performed in order to 
determine the efficacy of Ly6G tissue penetration and circulating neutrophil 
depletion. Sham and stroke mice received 500ug anti-Ly6G or isotype control 
antibody at 4, 24 and 48 hours after sham or ischemic stroke surgery. Cheek 
bleeds were performed on all mice at 24 hours and 48 hours, and blood was 
prepared for flow cytometry. Following red blood cell lysis, cells were stained as 
outlined in Chapter 3, and CountBrite (Thermofisher) counting beads were added 
to samples before analysis in order to determine absolute neutrophil numbers. In 
the treatment group that received anti-Ly6G antibody for neutrophil depletion, the 
surface epitope of Ly6G remains highly bound by the depletion antibody, 
masking the presence of neutrophils by traditional gating. Therefore, we 
developed an alternative gating strategy that did not rely on Ly6G for neutrophil 
identification (CD45+/CD11b+/SSCHigh/Ly6CIntermediate). Our alternate gating 
strategy is presented in Figure S2. At 72 hours, mice were sacrificed, and blood 
was obtained by cardiac puncture. To assess tissue penetration, spleen and 
bone marrow were also harvested. All three tissues were prepared for flow 
cytometry, and our alternative gating strategy was applied.  
 
Corner Test 
The corner test is a measure of integrated sensorimotor function, involving both 
sensory stimulation and motor response. The test was performed as described in 
Li et al. 2004, with slight modifications.200 The mouse was placed between two 
plastic pieces with dimensions of 12 x 24 inches. The two boards were placed at 
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an angle of 30° and gradually moved closer to the mouse, encouraging the 
subject to move into the created corner. This resulted in stimulation of the 
vibrissae on both sides of the mouse’s face, causing the mouse to rear up and 
turn back towards the open end. Each mouse was tested in 20 separate trials, 
and the percentage of right turns was calculated.  
 
Hanging Wire Test. In this test, mice utilize all four limbs to support their body 
weight on a wire-cage elevated 36 inches above a cage containing soft bedding. 
The time until the mouse fell was recorded, with an upper limit of 90 seconds. 
Mice unable to hang were excluded from the study. For trials involving aged 
mice, the average hang time was corrected for weight, to adjust for the weight 
variability within the cohort.  
 
Adhesive Removal Test. In this test, a small round adhesive circle measuring 
1cm was applied to the left forepaw of a mouse. The mouse was then placed 
alone in a clean cage. The time to remove the adhesive sticker was measured, 
with an upper limit of 5 minutes.  
 
Acute Infarct Quantification 
Aged animals were sacrificed 72 hours post-stroke. Following sacrifice, brains 
were removed and flash frozen at 80°C. Brains were then sliced into 2mm 
coronal sections, and stained with 1.5% 2,3,5 triphentyltetrazolium (TTC, Sigma-
Aldrich). Sections were fixed in 4% paraformaldehyde overnight before digital 
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imaging and infarct measurement (Sigma Scan Pro5) by a blinded investigator as 
previously described.134 
 
Lung Bacterial Burden Quantification. Aged mice (22 months) were subjected to 
sham or stroke surgery. 72 hours after stroke, mice were sacrificed, and lung 
tissue was removed using sterile technique. Tissue was homogenized and plated 
on blood agar for 24 hours before assessment of colony-forming units (CFUs). 
Bacterial burden was expressed as CFUs per gram of tissue. Anti-neutrophil 
depletion in these mice was confirmed by flow cytometry, utilizing the alternative 
gating strategy outlined above.  
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Figure S2. Alternative gating strategy for anti-Ly6G neutrophil depletion 
confirmation (blood). In order to identify neutrophils in the neutrophil depletion 
cohort, we utilized an alternative gating strategy. Live, single cells were selected 
for CD45 and CD11b expression to classify myeloid cells, followed by 
identification of neutrophils as Ly6CIntand SSCHigh cells, with inflammatory 
monocytes representing the Ly6CHigh and SSCInt population   
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5.4 Results 
Post-stroke Anti-Ly6G treatment successfully penetrates tissues and depletes 
circulating neutrophils. Although the efficacy of anti-Ly6G in depleting neutrophils 
in non-injury conditions has been well characterized, less is known regarding the 
ability of anti-Ly6G to significantly deplete neutrophils under conditions of high 
neutrophil production and release (e.g. during injury). In order to test whether 
anti-Ly6G was capable of producing adequate depletion, both sham and stroke 
mice were treated with either 200ug of anti-Ly6G, 500ug of anti-Ly6G or 500ug 
isotype control antibody at 4, 24 and 48 hours after stroke (Figure 23). Cheek 
bleeds were obtained at 24 and 48 hours, and cardiac puncture and tissue 
collection were performed at the 72-hour terminal sacrifice. Flow cytometry 
demonstrated that, while 200ug anti-Ly6G was capable of reducing neutrophil 
proportions in sham animals (Figure 23A), only 500ug of anti-Ly6G showed 
significantly depletion out to 72 hours post-stroke (p=0.0015, Figure 23B). As 
neutrophil proportion changes might be driven by alterations in other cell 
percentages, we also examined exact neutrophil counts using flow cytometry 
counting beads, confirming the proportional results and demonstrating that 
absolute neutrophil counts are significantly reduced by anti-Ly6G treatment 
(Figure 23C). The penetration of anti-Ly6G into known neutrophil reservoir 
tissues was also examined and showed that the vast majority of neutrophils in 
the blood, bone marrow and spleen are coated with anti-Ly6G antibody (masking 
the subsequent binding of flow-cytometry labeled anti-Ly6G) at 72 hours post-
stroke (p=<0.0001, Figure 23D). 
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Figure 23. Neutrophil depletion efficacy of anti-Ly6G. Young mice were 
subjected to sham or stroke MCAO (60 minutes), then treated with either isotype 
control antibody, 200ug of anti-Ly6G or 500ug of anti-Ly6G antibody I.P. at 4 
hours, 24 hours and 48 hours after stroke. Data was analyzed by two-way 
ANOVA, followed by Tukey’s multiple comparisons testing. A. Reduction of 
neutrophil proportions in treated sham animals. B. Reduction of neutrophil 
proportions in treated stroke animals. C. Absolute neutrophil counts in treated 
animals. D. Ly6G median fluorescence intensity in blood, spleen and bone 
marrow. n=3-4/grp. 
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Post-stroke anti-Ly6G treatment affects mortality in aged animals. Young (3 
months) and aged animals (24 months) were treated with 500ug anti-Ly6G 
antibody I.P. at 4, 24 and 48 hours post-stroke (Figure 24). No sub-acute 
mortality was observed in the young group (Figure 24A). Despite a trend towards 
improved mortality in both aged male and aged female animals, no significant 
effect of Ly6G was seen when assessed separately (Figure 24C, 24D). When 
aged male and female animals were pooled, anti-Ly6G treatment was found to 
significantly improve sub-acute mortality at 3 days (Figure 24B, p=0.03). 
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Figure 24. Anti-Ly6G treatment improves mortality in aged mice after 
stroke. Young (3 months) and aged (24 month) mice were subjected to 60 
minute MCAO, followed by treatment with either 500ug anti-Ly6G antibody or 
500ug isotype control antibody at 4, 24 and 48 hours post-stroke. A. Mortality in 
young animals, n=5/group. B. Mortality in male and female aged animals, n=9-
10/grp. C. Mortality in aged male animals, n=4-5/group. D. Mortality in aged 
female animals, n=5/grp.  
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Anti-Ly6G treatment improves long-term outcomes in aged, but not young, 
animals. As the stroke-induced mortality in 24-month old mice resulted in a 
significant survival bias, we then utilized slightly younger mice (21-22 months) to 
test the effects of anti-Ly6G on long term outcomes. Using the same treatment 
methodology, young (3 month) and aged (21-22 months) mice were subjected to 
60 minute MCAO stroke and followed out for two months (Figure 25). Animals 
without successful strokes or those with subarachnoid hemorrhage were 
excluded from the analysis. In young mice, no significant effects of anti-Ly6G 
treatment in long-term mortality (Figure 25A) or neurological deficits (Figure 
25B). In line with the neurodeficit data, young animals showed no benefit of anti-
Ly6G treatment on functional outcome after stroke by either corner testing 
(Figure 26A) or hang-wire testing (Figure 26B). 
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Figure 25. Anti-Ly6G treatment does not improve mortality or neurological 
deficit in young mice after stroke. Young (3 month) mice were subjected to 60 
minute MCAO, and received either 500ug of anti-Ly6G or 500ug of isotype 
control antibody I.P. at 4, 24 and 48 hours after stroke. A. Post stroke mortality 
was monitored out to 56 days post-stroke. B. Neurological deficits were 
measured at 7, 14, 21, 28 and 56 days post-stroke. N=6-7/group. 
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Figure 26. Anti-Ly6G treatment does not affect behavioral recovery after 
stroke in young animals. A. Serial corner testing at day 7, 14 and 56 post-
stroke in young mice after MCAO. B. Hang-wire strength testing in young mice 
after MCAO at day 7. N=6-7/group. 
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Figure 27. Anti-Ly6G treatment improves gross neurodeficit recovery after 
stroke in aged mice. Mortality (A) and neurological deficit score (B) were 
assessed in aged (21-22 month) male mice receiving 500ug of anti-Ly6G or 
isotype control antibody at 4, 24 and 48 hours after stroke. N=9/group 
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Anti-Ly6G treatment improves long-term behavioral outcomes in aged animals.  
Next, we examined the effects of anti-Ly6G treatment on long-term outcome in 
our aged mice (Figure 27). Despite no differences in long-term mortality (Figure 
27A), neutrophil depletion with anti-Ly6G significantly improved gross 
neurodeficit recovery after ischemic stroke in aged mice (Figure 27B). Aged 
animals, however, demonstrated significant improvement in corner testing at 28 
days (Figure 28A), adhesive removal testing at 7 and 28 days (Figure 28B) and 
hang wire testing at 14 and 28 days post-stroke (Figure 28C). Y-Maze, Barnes 
and Open Field Testing was also performed for both young and aged animals, 
but as no significant stroke vs. sham differences were seen in the primary testing 
variables (Correct Alternations in Y Maze, Latency to Escape in Barnes Maze, 
Percent Time in Center for Open Field Testing), these tests were not considered 
for assessment of therapeutic benefit. 
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Figure 28. Anti-Ly6G treatment improves behavioral recovery in aged 
animals after stroke. Behavioral testing of aged mice receiving anti-Ly6G or 
control antibody after ischemic stroke. Behavior was conducted weekly at the 
same time each day in a dimly lit, climate-controlled room. n=4-5/group. 
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Anti-Ly6G treatment does not affect long-term cerebral atrophy after ischemic 
stroke. Improvements in functional outcome after ischemic stroke after 
therapeutic delivery can be dependent or independent of gross tissue damage. 
As stroke size can significantly change stroke functional outcome and all 
secondary inflammatory sequelae, it is critical to determine whether anti-
neutrophil depletion reduces overall direct tissue damage. Cresyl violet staining 
for cerebral atrophy in brains taken two months after stroke demonstrated that 
anti-Ly6G treatment did not significantly affect brain atrophy in young or aged 
mice after ischemic stroke (Figure 29). 
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Figure 29. Anti-Ly6G treatment has no effect on long-term cerebral atrophy 
after ischemic stroke. Cresyl violet staining of brains taken from young and 
aged mice receiving either control antibody or anti-Ly6G treatment two months 
after ischemic stroke (n= 4-6/group).  
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Anti-Ly6G Improves Outcome in Aged Female Mice 
Importantly, sex is also known to play a role in inflammation and outcome 
after ischemic stroke. To that end, we also tested the efficacy of anti-Ly6G 
treatment on long-term stroke outcomes in female mice (Figure 30). Similar to 
aged males, despite no significant difference in long-term mortality (Figure 30A), 
aged female mice treated with anti-Ly6G showed significantly improved 
neurological deficits by day 14 after stroke, remaining significant at 28 days post-
stroke (Figure 30B). Further behavioral testing demonstrated a trend towards 
improved adhesive removal in anti-Ly6G treated aged females (Figure 30C), and 
a significant improvement in hang-wire test in anti-Ly6G treated females at day 
28 (Figure 30D).  
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Figure 30. Anti-Ly6G treatment improves outcomes in aged female animals 
after stroke. Aged female mice received treatment with either 500ug anti-Ly6G 
antibody or isotype control I.P. at 4, 24 and 48 hours after stroke. A. Post-stroke 
mortality of aged females. B. Neurological deficit measurements in aged female 
animals. C. Adhesive testing of aged female animals at 7 days and 28 days post-
stroke. D. Hang-wire strength testing of aged female animals at 7 days and 28 
days post-stroke. E. Atrophy analysis of CV stained slices taken 2 months post-
stroke. F. Representative CV images for atrophy quantification. N=3-6/group. 
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Anti-Ly6G Treatment Results in Significant Neutrophil Reduction in Aged Animals 
at 3 Days Post-Stroke. As dose optimization of anti-Ly6G therapy was performed 
in young animals, we next sought to confirm that neutrophil depletion via our 
treatment paradigm is equally efficacious in aged animals. Flow cytometry of 
blood taken from aged male mice 72 hours after ischemic stroke demonstrated 
that absolute neutrophil counts were significantly reduced in animals receiving 
anti-Ly6G (p=.02, Figure 31).  
 
Anti-Ly6G Treatment Does Not Affect Acute Tissue Injury in Aged Animals 
While no differences in tissue atrophy were seen after two months across all 
groups, we sought to confirm that our treatment had no effect on the initial injury 
size after ischemic stroke. Aged mice were subjected to 60 minute MCAO, and 
their brains were harvested at 72 hours (the peak of ischemic injury expansion) 
for acute infarct analysis. As shown in Figure 32, anti-Ly6G treatment did not 
significantly effect the size of the infarct itself, indicating that neutrophil depletion 
therapy likely mediates its beneficial effects in aged animals independently of 
direct cerebral tissue damage.  
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Figure 31. Anti-Ly6G Treatment Significantly Reduces Neutrophils in Aged 
Animals. Aged mice (22 months) were given 500ug anti-Ly6G I.P. at 4, 24 and 
48 hours after ischemic stroke. After 72 hours, mice were sacrificed and 
neutrophil counts were assessed by flow cytometry. * = p<0.05 
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Figure 32. Anti-Ly6G Treatment Does Not Alter Infarct Size in Aged 
Animals. Aged mice (22 months) were given 500ug anti-Ly6G I.P. at 4, 24 and 
48 hours after ischemic stroke. After 72 hours, mice were sacrificed, and brains 
were sectioned and stained with TTC to determine volumetric infarct size.  
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Neutrophil depletion significantly reduces the volume hemorrhagic transformation 
in aged mice after stroke. As neutrophil depletion did not reduce acute infarct 
volume or long-term atrophy post-stroke, we sought to examine other possible 
explanations for the improved recovery seen in treated aged mice. Hemorrhagic 
transformation after ischemic stroke is a common and serious complication, seen 
in both human patients and animal models. Our lab has previous shown that 
bone marrow transplantation of aged bone marrow into young mice increases the 
incidence of hemorrhagic transformation after stroke. In this experiment, aged 
mice were treated with either anti-Ly6G or control antibody after stroke induction. 
Seven days post-stroke, mice were sacrificed and brains were perfused and 
taken for histology. Volumetric quantification revealed that aged mice treated with 
anti-Ly6G showed significantly less hemorrhage into the ischemic tissue after 
stroke (Figure 33).  
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Figure 33. Neutrophil depletion significantly reduces hemorrhagic 
transformation after ischemic stroke. Aged mice received either anti-Ly6G or 
control antibody at 4, 24 and 48 hours after ischemic stroke. After seven days, 
mice were perfused and brains were removed and sliced. Visible hemorrhage 
was quantified by volumetric measurement. *=p<0.05, n=2-3/grp.  
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Neutrophil Depletion Does Not Significantly Increase Bacterial Burden in Aged 
Animals After Stroke. The leading cause of death in clinical stroke survivors is 
infection, secondary to widespread stroke-induced lymphopenia. As neutrophil 
depletion with anti-Ly6G is considered an immunosuppressive therapy, we 
elected to monitor body temperature and bacterial burden in aged stroke and 
sham mice receiving neutrophil depletion therapy (Figure 34). Anti-Ly6G 
treatment did not significantly alter body temperature in sham or stroke animals 
(Figure 34A). As predicted, bacterial burden in the lung increased significantly 
after ischemic stroke, likely secondary to stroke-induced immunosuppression 
(p=0.0042, Figure 34B). However, no difference was seen in bacterial burden 
between treated and control stroke animals.  
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Figure 34. Neutrophil Depletion Does Not Significantly Increase Lung 
Bacterial Burden in Aged Animals After Stroke. Aged mice (22 months) were 
given 500ug anti-Ly6G I.P. at 4, 24 and 48 hours after ischemic stroke. (A) 
Temperature was assessed daily by rectal thermometer (B). After 72 hours, mice 
were sacrificed, and lung lobes were harvested and plated to determine bacterial 
CFU.  
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5.5 Discussion 
 As predicted, we were able to achieve significant depletion of neutrophils 
in the circulation with anti-Ly6G administration. The majority of previous anti-
Ly6G studies were done using 200ug of anti-Ly6G in healthy animals or models 
of chronic inflammation. However, as stroke is an acute inflammatory condition 
associated with a dramatic upregulation in neutrophil production and release, we 
elected to test both the standard dose (200ug) and an elevated dose (500ug) 
previously described in an acute inflammatory model.201 Both doses produced 
significant reduction of circulating neutrophils up to 48 hours post-stroke. 
Ultimately, the 500ug dose was chosen as depletion remained significant out to 3 
days, more than 24 hours after the last antibody dose was given.  Anti-Ly6G also 
demonstrated good tissue penetration in the spleen and bone marrow, ensuring 
that neutrophils released from these tissues into circulation could also quickly be 
targeted for degradation.  
 In our pilot cohort, we examined differences in short-term (7 day) mortality 
between young (3 month) and aged (24 month) animals. Anti-Ly6G treatment 
significantly reduced post-stroke mortality in aged animals. As there was 0% 
mortality in the young animal group, mortality effects in young animals could not 
be assessed at this timepoint.  
 In our second, long-term survival cohort, young and aged animals were 
followed for two months after stroke. Given the exceedingly high sub-acute 
mortality (50% at 2 days) seen in 24-month old animals, we performed the 
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second set of experiments using younger mice (21-22 months). This enabled us 
to expand the cohort size available for behavior.  
 No effect of anti-Ly6G on mortality or neurological deficit scores was seen 
in young mice out to 2 months post-stroke. Interestingly, mortality rates were 
slightly higher in treated animals (34%) compared to control animals (15%), 
although this did not reach statistical significance.  
In aged animals, no significant effect of anti-Ly6G was observed on long-
term mortality out to two months post-stroke. This similarity in mortality rates 
enabled us to make comparisons of post-stroke outcome without concern for a 
survival bias. Anti-Ly6G was found to improve neurological deficit score recovery, 
with significance seen during 30-day testing.  
Behavioral tests conducted in young animals showed no significant effect 
of anti-Ly6G on recovery in young mice. However, testing in aged animals 
revealed a significant improvement in corner test, adhesive test and hang-wire 
test with anti-Ly6G treatment. These improvements were most significant in later 
timepoints after recovery, indicating that the depletion of neutrophils may be 
beneficial via an alteration in the healing process of the aging brain. In further 
support of this, no significant differences were observed in atrophy between anti-
Ly6G and control treated aged animals, suggesting that the mechanism of anti-
Ly6G treatment is not directly linked to a decrease in initial tissue damage. 
 Importantly, age-dependent sex differences in stroke incidence and 
outcome exist in clinical populations. As female stroke patients tend to be 
significantly older than men at the time of their stroke, elderly women experience 
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even higher stroke rates and poorer long-term functional recovery than men.202-
204 As sex differences in immunity and inflammation have been described in both 
humans and animal models, we also examined the efficacy of anti-Ly6G therapy 
in aged female mice.205 Similar to aged male mice, we found that female mice 
exhibited a significant improvement in neurological deficit scores with anti-Ly6G 
treatment. In addition, there was a significant improvement in hang-wire 
performance and a trend towards improved sensorimotor function by adhesive 
testing at day 28 post-stroke in the treatment group. These results demonstrate 
that, despite no significant benefits in young animals, anti-Ly6G depletion of 
neutrophils after stroke confers significant benefit to both aged male and female 
animals.  
Next, to better understand the effects of neutrophil depletion therapy in 
aged animals, we confirmed that anti-Ly6G significantly reduces circulating 
neutrophil counts in aged animals up to 3 days after ischemic stroke. As 
functional recovery tends to show significant improvement at later timepoints, 
and no treatment differences were seen in brain atrophy two months after stroke, 
we believe this protection may be mediated by an indirect pathway rather than 
direct, acute tissue preservation. To confirm our long-term studies showing no 
effect of anti-Ly6G on tissue atrophy, we performed acute infarct analysis at 72 
hours. These results, showing that anti-Ly6G does not alter the initial infarct size 
at peak expansion agrees with our long-term data, which together suggests that 
anti-Ly6G mediated protection in aged animals after ischemic stroke is indeed 
independent of initial infarct size. To this end, we examined whether anti-Ly6G 
145		
reduces hemorrhagic transformation, which has previously been shown to 
significantly worsen stroke outcome in human patients. Our experiment 
demonstrated that mice receiving neutrophil depletion therapy exhibited 
significantly less hemorrhage at 7 days after stroke compared to the control 
group.  
Finally, as stroke itself has been shown to increase the risk of infection, it 
is important to examine any significant immunosuppressive side effects when 
assessing therapeutic benefit. As neutrophils are an important part of immune 
protection under normal conditions, we wanted to examine whether neutrophil 
depletion after stroke would impair bacterial clearance and increase infection risk 
in aged mice. Our results demonstrated that anti-Ly6G treatment had no effect 
on temperature or bacterial burden after ischemic stroke, yielding early evidence 
that temporary neutrophil depletion in the acute stages of stroke may not put 
subjects at undue risk of serious bacterial infections.  
Despite this evidence that neutrophils play a greater pathogenic role in 
aged animals and that they represent a viable therapeutic target in aging 
populations (Figure 35), the mechanism by which aged neutrophils confer 
greater damage remains unknown. In the final Chapter of our work, we will 
examine potential causes behind the age-specific benefits of neutrophil depletion 
in ischemic stroke.  
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Figure 35. Graphical abstract of findings from Chapter 5 
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6.1 Overall Conclusions  
 Ischemic stroke is a complex and multifactorial injury that results in 
profound and permanent damage to the brain, our most sensitive and essential 
organ. As with many leading causes of death, stroke is largely a disease of the 
aging population. While the peripheral inflammatory system has been implicated 
in secondary damage after ischemic stroke, the complex interplay between 
aging, systemic inflammation and tissue injury remains critically understudied. 
The work presented in this thesis endeavors to close the gap in knowledge 
regarding the effects of aging on neutrophil biology, specifically focusing on how 
the neutrophil injury response may undergo a detrimental and destructive shift as 
an organism ages.  
In Chapter 1, we explored the current state of knowledge regarding the 
overwhelming social and economic impact of ischemic stroke on today’s society. 
The primary pathologic mechanisms of cerebral ischemia were discussed, 
including the significant limitations of currently available treatments for ischemic 
stroke. In particular, we highlighted the recent focus on sterile inflammation and 
the role of innate immune neutrophils in stroke pathology and outcome. 
Neutrophils and their heavy arsenal of damaging immune defenses have been 
previously studied as a therapeutic target in ischemic stroke, but numerous 
promising animal studies have yielded no effective clinical therapies to date.   
We hypothesized that the optimal study of neutrophils in ischemic stroke 
pathology would require two additional factors missing from most current 
research: (1) the ability to specifically and transiently target neutrophils and (2) 
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the examination of therapeutic outcomes in both young and aged animals. In light 
of this, we designed our experiments to delineate the effects of age on stroke 
outcome in animals and humans, with specific investigation into the role of aging 
on neutrophil biology and the implications of age-related changes in neutrophil 
function on ischemic stroke pathology and outcome.  
In Chapter 2, we confirmed the significant and robust relationship between 
advanced age and poor outcomes after ischemic stroke, including the elevated 
risk of death or significant disability in older stroke patients. We found that 
neutrophil counts increase significantly in the circulation of stroke patients within 
24 hours of injury, and that this increase is positively associated with greater 
stroke severity. This indicates that neutrophil-targeted therapies may yield 
greater benefit in patients experiencing moderate-to-severe strokes, a fact which 
should be carefully considered when designing future clinical trials.  
We then confirmed that the relationship between advanced age and poor 
stroke outcome could be replicated in an experimental model of ischemic stroke, 
enabling us to examine the role neutrophils may play in age-related stroke 
pathology. Young animals were found to have significantly larger strokes and a 
higher degree of edema than their aged counterparts. As seen previously, 
despite their smaller strokes, aged animals experienced significantly higher 
mortality, poorer weight recovery, greater neurological deficits and impaired 
behavioral recovery compared to young animals. As age-related differences in 
neutrophil pathogenicity after stroke could result from increased neutrophil (1) 
quantity or (2) pro-inflammatory quality, we then used flow cytometry to measure 
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the infiltration of neutrophils into the brain of young and aged stroke animals. No 
significant difference in the absolute number of brain-infiltrating neutrophils was 
seen in aged animals compared to young. In light of this, we focused subsequent 
studies on the effects of age on neutrophil pro-inflammatory functions.  
In Chapter 3, we examined the effects of age on two potential drivers of 
enhanced neutrophil damage after stroke: (1) inflammatory cytokine and 
chemokine production and (2) reactive species generation and detoxification. Ex 
vivo stimulation of neutrophils from young and aged mice demonstrated that, 
although neutrophils release a wide variety of inflammatory cytokines and 
chemokines upon stimulation, age does not significantly affect the release of 
neutrophil-associated inflammatory factors.  
Age was also found to have no influence on the levels of enzymes that 
generate (NOX2, iNOS) or detoxify reactive species (SOD1, catalase) in bone 
marrow neutrophils by Western Blot. Similarly, age did not alter the ability of 
bone marrow neutrophils to produce reactive species upon ex vivo stimulation.  
However, we found that age did augment reactive species production in 
circulating blood neutrophils. Most importantly, brain-infiltrating neutrophils taken 
from aged animals after stroke were found to contain significantly higher levels of 
reactive species than those from young animals. In line with our previous 
experiments, this phenomenon was found to be specific to activated neutrophils 
in the brain, as bone marrow neutrophils from the same stroke animals showed 
no significant age difference in reactive species content.  
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This data suggested to us that age-related changes in neutrophil function 
may be a product of their environment, rather than an innate, cell-intrinsic 
change. In Chapter 4, we studied the effects of age on neutrophil-activating 
factors in the circulation in both mice and humans after ischemic stroke. We 
found that aging results in an increase in neutrophil proportions across multiple 
organs, with aged animals showing significantly higher neutrophil increases in 
off-target organs (spleen and lungs) after ischemic stroke.   
In order to understand the cause of this age-related neutrophil skewing, 
we examined the effects of host age on neutrophil chemokine receptors and 
circulating levels of their associated ligands. Circulating neutrophils from aged 
animals had lower surface levels of the bone-marrow homing receptor CXCR4, 
despite similar levels of the circulation-promoting receptor CXCR2. Interestingly, 
aged stroke mice had decreased serum levels of the CXCR4 ligand CXCL12 
(which promotes bone marrow homing of “exhausted”, hyper-reactive 
neutrophils), despite no differences in the levels of CXCL2 (the ligand for CXCR2 
that promotes egress of neutrophils from the bone marrow).  Levels of surface 
CD44, an adhesion molecule important in the normal circadian clearance of 
circulating neutrophils, were also significantly lower on neutrophils taken from 
aged animals. These results suggest that age-associated neutrophil-skewing in 
the blood may result from a failure to remove exhausted, primed neutrophils from 
circulation.  
As neutrophils with this primed surface phenotype have been shown to 
respond quickly and more robustly to inflammatory stimulus, it is possible that 
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they may also be capable of greater off-target tissue damage under conditions of 
excessive inflammation, including ischemic stroke. It has been suggested that 
the abnormal accumulation of primed circulating neutrophils can result from 
chronic, low-level “Inflammaging.” Inflammaging is characterized by the higher 
baseline levels of inflammatory cytokines (like IL-6) seen in aged organisms 
compared to their younger counterparts. 
We measured IL-6, CXCL1 (the murine homolog of human IL-8) and G-
CSF in mice after ischemic stroke. Both age and stroke had a significant 
interactive effect on IL-6 and G-CSF levels in mice, with augmented post-stroke 
increases seen in aged mice when compared to young mice. Serum levels of 
CXCL1, the major chemotactic factor for neutrophils, were found to be 
significantly higher in the circulation of aged animals, potentially explaining the 
neutrophilia seen in aged animals at baseline and following ischemic stroke.  
Taken together, these studies indicate that aging (1) increases the 
proportions of neutrophils in the blood, bone marrow, lung and spleen at 
baseline, (2) augments post-stroke neutrophilia in off-target end organs, (3) 
increases levels of factors (IL-6, CXCL1, G-CSF) involved in neutrophil activation 
and entry into circulation and (4) decreases mediators of normal neutrophil 
clearance (CXCR4, CD44, CXCL12).  
Given our findings in mice, we then examined whether similar increases in 
neutrophil-activating cytokines could be observed in human stroke patients. As 
predicted, levels of IL-6 and IL-8 were acutely increased in stroke patients 
compared to controls. Circulating levels of these cytokines were positively 
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associated with increasing patient age, with advanced age remaining a strong 
independent predictor of IL-8 levels even after adjustment for confounding 
factors.  
RNA sequencing analysis of patient whole blood demonstrated that 
neutrophil degranulation was the most upregulated gene pathway in stroke 
patients compared to controls, and the second-most upregulated gene pathway 
in older stroke patients compared to their younger counterparts. These studies 
demonstrate that older stroke patients have (1) increased serum levels of 
neutrophil-activating cytokines, which are capable of stimulating adhesion, 
degranulation and reactive species generation and (2) increased expression of 
genes involved in neutrophil degranulation. 
In Chapter 5, we performed experiments to assess whether neutrophils 
play a causative role in poorer outcome in aged animals after ischemic stroke. 
We utilized anti-Ly6G, a monoclonal antibody to the neutrophil-specific Ly6G 
receptor, to deplete circulating neutrophils. This paradigm was chosen to 
increase clinical translatability and to reduce the likelihood of adverse effects. 
First, the antibody can be given specifically post-stroke (unlike a permanent 
knockout model, where depletion is lifelong), best mirroring the window in which 
a clinical therapeutic agent would be used (4 hours post-injury). Second, the 
depletion is transient in nature, allowing circulating levels of neutrophils to return 
to normal within three days of the final dose, when the height of neutrophil-
activating inflammatory signaling has passed. This transient depletion enabled us 
to study the acute effects of neutrophil depletion on stroke outcome while 
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reducing the likelihood of excessive immunosuppression and increased infection 
risk.  
 High dose anti-Ly6G was found to significantly deplete neutrophils up to 
three days after ischemic stroke in both young and aged mice. The antibody was 
found to penetrate into both the spleen and bone marrow, two reservoirs of naïve 
neutrophils, ensuring that newly released neutrophils were targeted for clearance 
upon entering circulation. In our first cohort, we found that anti-Ly6G treatment 
significantly reduced overall acute mortality in aged animals (including both male 
and female aged animals, 24 months of age). As there was no mortality in our 
young cohort out to 7 days, mortality effects could not be assessed.  
Due to the high mortality in the aged control groups from Cohort 1, we 
elected not to conduct functional testing in this cohort to prevent the introduction 
of survival bias. Instead, we repeated the experiment using slightly younger aged 
mice (20 months) and extended the follow-up period to two months.  
In young animals, we observed no effect of neutrophil depletion therapy 
on mortality, gross neurological deficit and functional outcome after stroke. 
However, in aged male animals, we found that neutrophil depletion significantly 
improved neurological deficit recovery and functional outcomes out to two 
months post-stroke. Similar beneficial effects were seen in aged female mice 
receiving neutrophil depletion, with the treatment group exhibiting significantly 
better long-term functional recovery compared to control. To our surprise, these 
improved outcomes in our aged neutrophil depletion group occurred 
independently of changes in long-term tissue atrophy. To confirm that anti-Ly6G 
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did not alter the size of tissue injury, we measured acute infarct size at 72 hours 
in an additional cohort of aged animals and found that anti-Ly6G had no effect on 
infarct size at the time of peak injury expansion. 
 It has been reported that poor outcome after ischemic stroke can also 
result from secondary hemorrhagic transformation into damaged brain tissue. We 
have previously observed that aged mice experience higher rates of hemorrhagic 
transformation than young mice, and that transplantation of aged bone marrow 
into young mice increases the rate of hemorrhagic transformation. In our studies, 
neutrophil depletion significantly reduced the degree of hemorrhagic 
transformation in aged mice at 7 days post-stroke, indicating that anti-Ly6G 
therapy may improve ischemic stroke outcome in aged animals by reducing 
neutrophil-mediated damage at the level of the blood-brain-barrier, limiting 
hemorrhagic transformation and preserving tissue function.  
Ischemic stroke causes profound lymphopenia and lymphoid cell anergy 
throughout the body, leaving patients susceptible to a wide variety of infections. 
Infection represents the leading cause of death in stroke survivors, particularly in 
aged patients who already exhibit baseline immunodeficiency compared with 
their younger counterparts. As such, the consequences of immunosuppressant 
side effects must be considered when developing potential therapies for stroke 
patients. As neutrophils are a critical component of immune protection against 
certain pathogens, we sought to determine whether neutrophil depletion impairs 
bacterial clearance. Given that ventilator-associated and aspiration pneumonia 
are common and serious post-stroke infections, we elected to assess bacterial 
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burden in the lungs. As previously reported, stroke significantly increased the 
bacterial load within the lungs, but neutrophil depletion treatment did not 
exacerbate post-stroke bacterial burden.  
As a whole, these experiments suggest that age increase the 
pathogenicity of neutrophils in ischemic stroke, independent of alterations in 
stroke size. In particular, the improved functional recovery seen in anti-Ly6G 
treated animals after ischemic stroke may result from a decrease in neutrophil-
mediated hemorrhagic transformation. Importantly, neutrophil depletion therapy 
does not appear to significantly impair bacterial clearance in stroke animals, 
indicating that it may represent a relatively safe form of immunosuppressive 
therapy for ischemic stroke.  
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6.2 Future Investigations 
What drives neutrophil aging? Our data indicate that neutrophil biology changes 
with aging, resulting in an exacerbated detrimental phenotype after ischemic 
stroke. However, some key questions remain unanswered. First, do specific 
cellular processes contribute to the detrimental neutrophil phenotype after 
ischemic stroke in aged animals? Our data indicates that reactive species 
production in neutrophils from aged animals is heightened, indicating that 
reactive species as a strong candidate for increased age-related neutrophil 
pathogenicity in ischemic stroke. To that end, future experiments (described 
below) should investigate whether reactive oxygen species production or reactive 
nitrogen species production are necessary for the detrimental phenotype of aged 
neutrophils. In addition to reactive species production, neutrophils also engage in 
several other critical defensive processes, including the generation of NETs and 
the release of antimicrobial and degradative granule proteins. Further 
experiments should determine whether NET production, or key damaging 
granule proteins, are critical to the heightened detrimental role of neutrophils 
(described below). Although neutrophils are capable of phagocytosis, it is 
considered a minor function, and does not represent a likely cause of age-related 
neutrophil pathogenicity. The second important question to be answered is 
whether age-related differences are inherent to the cells themselves, or a product 
of the aging environment. As discussed below, future experiments using bone 
marrow chimera mice will be designed to determine whether age-related 
differences in neutrophil function are intrinsic (present during neutrophil 
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differentiation and maturation) or extrinsic (the result of phenotypic changes in 
neutrophils secondary to an aging environmental milieu). If changes to neutrophil 
phenotype with age are found to be neutrophil intrinsic (present in naïve 
neutrophils and progenitor cells from aged animals), a third set of future 
directions will be explored. In these experiments,  
Third, we will investigate whether changes in neutrophil trafficking, 
mobilization and clearance play a role in heightened neutrophil pathogenicity with 
age. While intrinsic neutrophil pathogenic processes may play a critical role in the 
detrimental phenotype seen in ischemic stroke, it is also possible that a loss of 
regulation at the level of neutrophil release and clearance, perhaps secondary to 
impaired macrophage function, might drive the excessive neutrophil response 
seen after injury in aged animals. To this end, future experiments will investigate 
the effect of age on neutrophil trafficking, mobilization and clearance, and 
interrogate several factors identified in this thesis work that may contribute to 
altered neutrophil movement and regulation, as described below (CXCL1, IL-6, 
G-CSF). Fourth, we will determine whether common co-morbidities seen in aged 
mice and humans, including hyperlipidemia and hyperglycemia, specifically 
contribute to the detrimental neutrophil phenotype in ischemic stroke. 
Our data demonstrates clear age-related changes in neutrophil 
phenotype, and their contribution to ischemic stroke pathology. It remains 
unknown whether specific neutrophil functions (RS production, NETs, granule 
proteins) and/or altered neutrophil behavior (aberrant trafficking, excessive 
mobilization, impaired clearance) underlie this difference. Furthermore, it remains 
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unknown whether these changes are intrinsic to neutrophils and their progenitor 
cells, or a result of the exposure of neutrophils to a heightened inflammatory 
environment in the aged host, including exposure to high glucose and lipid levels. 
The experiments described below aim to elucidate the answers to these 
questions.  
 
Elucidating the Mechanism and Impact of Augmented Neutrophil-Derived 
Reactive Species Production in Aged Animals After Stroke.  
Our studies suggest that neutrophils from aged animals are primed to 
produce augmented levels of reactive species compared to those from young 
animals. Previous studies in animals have found that neutrophils are a major 
source of reactive species in the brain during ischemia and reperfusion.84, 206 
Reactive species are believed to cause further brain injury via damage to 
cerebral vessels, glial cells and neurons, and are believed to contribute 
significantly to secondary hemorrhagic transformation.8 Yet despite the success 
of free-radical scavenging agents in animal models of ischemic stroke188, 190, 207, 
208, these non-specific pharmacologic agents have failed to improve outcome in 
ischemic stroke patients.186, 189  
The failure of these agents, which involve global inhibition of free radicals, 
is likely due to two factors. First, pharmacologic inhibition of free radicals results 
in their global suppression, leading to significant non-specificity. While neutrophil-
derived reactive species may play damaging roles in ischemic injury, free 
radicals are involved in many normal physiological processes in many cell types, 
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including the propagation of intracellular signaling.  Second, the pre-clinical 
therapeutic studies only utilized young animals, despite the fact that stroke is a 
disease of age.  One clinical study specifically highlighted the use of young, 
healthy animals in pre-clinical studies as a potential reason for the therapeutic 
failure of radical scavenging therapies in elderly ischemic stroke patients.186, 189   
In the context of ischemic stroke, we found that depletion of neutrophils 
after injury onset resulted in improved functional recovery in aged, but not young 
animals. In addition, age-related secondary hemorrhagic transformation was 
attenuated in aged animals receiving neutrophil depletion therapy.  Our results 
indicate that there is a uniquely detrimental role of neutrophils in aged subjects 
after stroke. As neutrophils from aged mice were found to produce significantly 
higher levels of reactive species than neutrophils from young mice, and reactive 
species production has been linked to hemorrhagic transformation and tissue 
damage in ischemic stroke, we hypothesized that age-driven alterations in 
neutrophil reactive species production may contribute to the poorer outcomes 
seen in aged animals after ischemic stroke.  
However, whether neutrophil specific reactive species production is a 
causative factor in these poor outcomes remains unknown. In order to address 
this, future studies involving neutrophil-specific knockout of key reactive species-
generating enzymes, including neutrophil NADPH oxidase and inducible nitric 
oxide synthase, should be conducted (Figure 36).  
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Figure 36. Schematic representation of future directions investigating whether 
neutrophil reactive species generation is specifically responsible for the poorer 
outcomes seen in aged animals after ischemic stroke.   
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Neutrophil NADPH Oxidase. The generation of superoxide (O2-) radicals 
after ischemic stroke is believed to contribute significantly to tissue pathology 
after ischemic stroke.209 The multi-subunit NADPH oxidase is responsible for 
generating superoxide within neutrophils, with NOX2 serving as the catalytic 
subunit.210 Global inhibition of NOX2 in young animals by pharmacologic 
(apocyanin) or permanent genetic methods has been shown to reduce stroke 
size and neutrophil infiltration.211, 212 In order to understand whether the 
generation of reactive oxygen species by NADPH oxidase contributes to the 
poorer outcomes seen in aged stroke animals, improved genetic models are 
needed.  
Given the importance of NADPH oxidase in normal intracellular signaling 
across a variety of cells, the ideal genetic model would allow knockout of NOX2 
specifically in neutrophils.  As the timing of neutrophil infiltration and 
pathophysiology may differ between young and aged mice, this model should 
also be inducible, rather than permanent. Use of an inducible knockout, such as 
the Tetracycline-On system, will allow the study of neutrophil-derived reactive 
species in both the acute, sub-acute and chronic phases of post-stroke 
inflammation. Neutrophil-specific gene targeting can be accomplished via a 
MRP8 (S100A8) transgene, which was recently shown to be result in highly 
specific gene knockout in neutrophils.213  
To create a neutrophil-specific, inducible knockout system, mice carrying 
three component alleles are required: (1) a Tet-On tetracycline-dependent 
transcription factor (rtTA) under the regulation of the neutrophil-specific MRP8, 
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(2) a TetO-Cre transgene and (3) the floxed NOX2 allele. Treatment with 
doxycycline will result in binding of the rtTA protein to the TetO sequence, 
activating the Cre and resulting in knockout of NOX specifically in neutrophils.214 
As neutrophils take approximately 4-6 days to mature, experiments to confirm the 
efficacy and timing of doxycycline-induced NOX2 knockout should be performed 
to determine the dosing schedule needed to achieve neutrophil-specific NOX2 
inhibition during the acute (0-3 days), sub-acute (4-7 days) and chronic (7-28 
days) periods post-stroke.  
After optimization, young (3 month) and aged (20-22 month) transgenic 
mice will be treated with or without doxycycline, and subjected to MCAO stroke 
(Figure 37). If our hypothesis is correct, acute inhibition of neutrophil NOX2 by 
doxycycline treatment (and the downstream suppression of neutrophil reactive 
oxygen species generation) should significantly improve functional recovery 
specifically in aged mice, with little effect in young mice. Secondary experiments 
should be performed using anti-Ly6G neutrophil depleting antibody to determine 
whether NOX2 inhibition and neutrophil depletion have synergistic effects, no 
additive effect or antagonistic effects on outcome in aged mice after stroke.  
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Figure 37. Schematic representation of strategy to evaluate the role of 
specific neutrophil functions in the enhanced pathogenicity of neutrophils in aged 
animals after stroke. In this example, either NOX2 (NADPH Oxidase) or iNOS 
(inducible nitric oxide synthase) are temporarily inhibited in a Tet-On system by 
the delivery of doxycycline prior to ischemic stroke. These experiments will 
evaluate whether the production of neutrophil reactive oxygen species (ROS), 
reactive nitrogen species (RNS) or both are directly involved in the enhanced 
neutrophil-mediated damage seen in aged animals after stroke. 
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Inducible Nitric Oxide Synthase. While reactive oxygen species generation 
via NOX2 represent a powerful mechanism of reactive species generation after 
stroke, reactive nitrogen species (RNS) are also believed to play a significant role 
in ischemic stroke pathology.215 Two of the most common RNS are nitric oxide 
(NO) and peroxynitrite (ONOO-), both of which have been found at high 
concentrations within the brain after stroke.215 Three different isoforms of nitric 
oxide synthase (NOS) can produces NO. Endothelial NOS (eNOS) produces 
consistent, low levels of NO that help to regulate normal vascular physiology, and 
the constitutive expression of neuron-derived NOS (nNOS) in the brain serves to 
regulate synaptic plasticity and local blood flow.216  
Inducible NOS (iNOS), which is highly expressed in immune cells upon 
inflammatory stimulation, is believed to play a significant role in injury after brain 
ischemia. iNOS produces very high levels of NO, which can then combine with 
superoxide (O2-) to produce highly reactive peroxynitrite (ONOO-). High levels of 
these RNS are neurotoxic, resulting in both direct cell death and further 
exacerbation of blood-brain-barrier breakdown.215 Global genetic or 
pharmacologic inhibition of iNOS has previously been shown to reduce tissue 
injury and improve outcome in rodent models of ischemic stroke.62, 217  
As these methods resulted in global loss of iNOS function and were 
conducted in young animals, the contribution of neutrophil-derived iNOS to stroke 
pathology in clinically-relevant aged animals remains unknown. As our data 
showed that neutrophils from aged animals produce significantly higher levels of 
intracellular reactive species (including both RNS and ROS), it is possible that 
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this phenomenon is driven in part by changes in iNOS function with age. To test 
whether iNOS contributes to the age-related increase in neutrophil reactive 
species production and pathogenicity after ischemic stroke, a doxycycline-
inducible, neutrophil-specific knockout of iNOS must be used (methods and 
experimental plan as described previously).  
 
The Effects of Age on Other Pathogenic Neutrophil Functions 
 In addition to an increase in reactive species production, age-related 
changes in the production of neutrophil extracellular traps (NETs) and the 
composition of neutrophil granule proteins may contribute to poorer stroke 
outcomes in aged animals (Figure 38). Although not considered within the scope 
of this study, understanding the effects of age on these neutrophil functions may 
provide further insight into the exacerbated neutrophil pathogenicity seen in our 
aged animals.  
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Figure 38. Schematic representation of future directions investigating whether (1) 
neutrophil NETosis and/or (2) degradative neutrophil granule proteins specifically 
contribute to the poorer outcomes seen in aged animals after ischemic stroke.  
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NETosis. During conditions of strong inflammatory stimulus, including 
infection and major tissue injury, neutrophils can undergo a specialized form of 
death known as NETosis. During this process, neutrophils cast out their nuclear 
chromatin, which is studded with histones and anti-microbial proteins. NETs have 
been shown to have protective functions during infection, via their ability to trap 
and damage microorganisms. However, NETosis has also been observed under 
conditions of sterile injury, including ischemic stroke, where it is thought to 
contribute to the propagation of inflammation and further tissue injury. Given the 
relationship between high intracellular RS levels and increased NETosis, future 
studies should examine the effects of age on neutrophil NET production and 
NET-mediated damage.  
Several methods should be utilized in order to fully assess whether age 
has significant effects on neutrophil NET production. Neutrophils must first be 
isolated from the bone marrow and circulation of young and aged animals, as 
described in our previous experiments. Cells are then stimulated with PMA for 
four hours, to induce cell death and the release of neutrophil NETs, neutrophil 
chromatin studded with neutrophil elastase (NE) and other granule proteins 
(NETs).218, 219 The presence and structure of NETs can then be confirmed by 
microscopy.220-222 As immunohistochemistry can be difficult to quantify, two 
alternative methods can then be utilized to examine potential quantitative 
differences in NET production between young and aged neutrophils.   
First, the activity and protein levels of NET component proteins, 
particularly NE, can be used as surrogate NET markers. In this assay, soluble 
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NE is washed away after 4 hours of ex vivo stimulation with PMA, and bound 
NETs are dissociated by the addition of S7 nuclease. The activity of NE released 
from dissociated NETs can then be assessed by the addition of a substrate, 
which will produce a colorimetric produce after cleavage by NE.218, 219 These 
samples can also be run in an ELISA for NE, to yield information about the 
quantity of NE.223 NET formation can also be quantified by flow cytometry by co-
staining for extracellular DNA and myeloperoxidase (MPO), a strategy which has 
been shown to correlate well with results obtained from established microscopy-
based methods.224  
Using the above methods, a timecourse of NET formation (from 0 – 4 
hours of stimulation) and dosage response (from 0 – 200 nM PMA) should be 
performed on neutrophils from young and aged mice to determine whether (1) 
aged neutrophils produce greater quantities of NETs and (2) whether aged 
neutrophils die and produce NETs at lower levels of stimulation or duration 
compared to young animals. If age-related differences in NET formation are 
observed, the next step will be to determine whether age-related differences in 
neutrophil NET formation contribute to the poor outcomes seen in aged animals. 
Stroke outcomes can be studied in young and aged transgenic mice (as 
previously described), using a mouse model with an inducible, neutrophil-specific 
knockout of mouse peptidylarginine deiminase 4 (PAD4), a protein that has been 
demonstrated to be necessary for NETosis.225 
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 Neutrophil Granule Contents. In addition to the release of reactive species 
and NETs, neutrophils also release several types of granules upon inflammatory 
stimulation. As previously discussed, these granules contain a wide variety of 
anti-microbial and inflammatory response proteins.226 Several of these proteins, 
including haptoglobin and lactoferrin, help to control stroke-induced inflammation 
by binding and sequestering inflammatory cytokines and toxic factors.227, 228 
Other factors, including the tissue degenerating enzymes MMP-9 and NE, 
contribute to further tissue damage and inflammation after ischemic stroke.229, 230  
 MMP-9, a degradative enzyme expressed at high levels in neutrophils, is 
of particular interest in ischemic stroke as it has been linked to disruption of the 
blood brain barrier and secondary hemorrhagic transformation.231 As our lab has 
seen a higher rate of hemorrhagic transformation in aged animals compared to 
young, and work previously described in this dissertation found a reduction in 
hemorrhagic transformation after treatment with anti-Ly6G, further investigation 
into age differences in neutrophil MMP-9 expression and activity is warranted. In 
addition, to determine the potential contribution of MMP-9 to the poor stroke 
outcomes seen in aged animals, our inducible, neutrophil-specific knockout 
model can be employed to determine whether loss of MMP-9 is preferentially 
beneficial in aged mice after stroke. A similar strategy can be employed to 
examine the contribution of other detrimental neutrophil granule proteins, 
including NE, proteinase-3, cathepsin G and myeloperoxidase.232  
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Determining Whether Age-Related Neutrophil Pathogenicity Is an Intrinsic (Cell-
Inherent) or Extrinsic (Environmental) Phenomenon. 
Neutrophil Intrinsic vs. Environmental Factors. Our data (Chapter 5) 
suggests that age increases the pathogenic impact of neutrophils after ischemic 
stroke. However, it is important to note that the increase in reactive species 
production seen in aged neutrophils compared to young was only observed in 
circulating and brain-infiltrating neutrophils, with no significant age differences 
seen in cells derived from the bone marrow. These results suggest that 
enhanced reactive-species production may not be inherent to aged neutrophils, 
but rather a product of altered neutrophil mobilizing and activating factors in the 
aged circulation.  
To that end, we can perform bone marrow chimera (BMC) experiments in 
order to determine whether the age-related increase in neutrophil RS production 
(and other neutrophil functions, as described above) is cell intrinsic or dependent 
on the aged host milieu. For these experiments, young and aged mice will be 
irradiated before reconstitution with bone marrow cells from young or aged donor 
(GFP+). After eight weeks, immune system reconstitution can be confirmed by 
cheek bleed flow cytometry, to check for the presence of circulating GFP+ donor-
derived immune cells in the recipient mice.  Four experimental groups will be 
generated: Young Recipient-Young Donor (YR-YD), Young Recipient-Aged 
Donor (YR-AD), Aged Recipient-Young Donor (AR-YD) and Aged Recipient-
Aged Donor (AR-AD). Each group will be subjected to stroke or sham surgery, 
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and will be randomized to receive anti-Ly6G treatment or isotype control at 4, 24 
and 48 hours post-stroke.     
If the age-related increase in neutrophil RS and pathogenicity in ischemic 
stroke are cell intrinsic, we would expect to see that both groups of animals with 
age-derived neutrophils (AR-AD and YR-AD) would have higher levels of RS in 
brain-infiltrating neutrophils after ischemic stroke. In addition, we would expect 
that both AR-AD mice and YR-AD mice would have poorer functional outcomes 
than their counterparts receiving young bone marrow (AR-YD and YR-YD, 
respectively). We would expect that this effect would be ameliorated in mice 
receiving neutrophil depletion therapy with anti-Ly6G, as the damaging effects of 
age-derived neutrophils would be suppressed.   
Conversely, if the age-related increase in neutrophils RS and 
pathogenicity in ischemic stroke are dependent on the surrounding pro-
inflammatory milieu of the aged host, we would expect to see that both groups of 
aged animals (AR-AD and AR-YD) would have higher brain-infiltrating neutrophil 
RS levels than young animals (YR-AD, YR-YD). Furthermore, we would expect 
to see poorer outcomes in both aged groups compared to their young 
counterparts (AR-YD worse than YR-YD, AR-AD worse than AR-YD), and an 
improvement in behavioral recovery in both aged mouse groups after treatment 
with anti-Ly6G, which would be absent in the young mouse groups. 
A third possibility exists, in which both age-related intrinsic neutrophil 
changes and alterations in the aging milieu contribute to neutrophil pathogenicity 
after ischemic stroke. In that case, we would expect to see that aged mice 
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receiving aged bone marrow (AR-AD) would have the highest levels of brain-
infiltrating neutrophil RS, the poorest stroke outcomes, and the best response to 
anti-Ly6G treatment out of the four groups. AR-YD mice, which lack aged 
neutrophils but retain an aged inflammatory milieu, would show a milder RS 
phenotype and better outcomes than AR-AD. Young mice receiving aged marrow 
(YR-AD) would show higher levels of neutrophil RS and poorer outcomes than 
YR-YD mice, which would be expected to have the lowest levels of RS in brain 
infiltrating neutrophils, the best overall stroke outcomes and receive minimal 
benefit from anti-Ly6G therapy.  
If the aged host milieu is shown to be either necessary or sufficient for 
exacerbated neutrophil reactive species generation and pathogenicity after 
ischemic stroke (discussed above), our work has already highlighted several 
candidate circulating factors for age-related alterations in neutrophil pathogenicity 
that will warrant further examination. If our experiments indicate that age-related 
enhancement of neutrophil pathogenic functions and disease pathogenicity are 
not a result of the aging environment, we must then explore the possibility that 
these changes are cell- intrinsic. Several theories on the cause of cellular aging 
have been proposed, which can be largely split into two categories – those that 
define aging as a programmed cellular process, and those that hypothesize that 
aging results from the accumulation of cellular damage over time. 
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Investigating Excessive Neutrophil Mobilization, Hyperactivation and Delayed 
Clearance in Aged Animals 
Neutrophil Mobilization. During a profound systemic inflammatory insult 
like ischemic stroke, neutrophils are released en masse from the bone marrow 
into the circulation. In concert, high levels of inflammatory cytokines (TNF-α, IL-
1β, IL-6) and growth factors (G-CSF) upregulate the new generation of bone 
marrow neutrophils and suppress the apoptosis of circulating neutrophils to meet 
the increased demand.233 Down-regulation of the bone marrow retention 
chemokine CXCL12 coupled with upregulation of CXCL1 and CXCL2 promote 
the release of neutrophils into the blood.234, 235 Due to the suppression of 
neutrophil apoptosis by factors like IL-6 and G-CSF and the decrease in bone 
marrow retention signals (CXCL12/CXCR4), the negative feedback control on 
neutrophil production is circumvented. This breakdown in neutrophil homeostasis 
is thought to benefit organisms during times of infection, where large numbers of 
neutrophils are required for protection.  
However, during conditions of extreme systemic inflammation like 
ischemic stroke, these processes are thought to cause severe functional 
abnormalities in neutrophil biology that both impair their ability to fight infection 
and result in their inappropriate and sustained recruitment into tissue, resulting in 
significant secondary damage.236 In this body of work, we found that bone 
marrow retention signals (CXCL12/CXCR4) were significantly decreased in aged 
animals. These findings highlight the potential utility of chemotactic pathways as 
targets for ischemic stroke therapy in aged patients.  
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Age-related decreases in normal return of primed neutrophils to the bone 
marrow may contribute to the (1) hyperactive neutrophil phenotypes and (2) the 
pathogenicity of neutrophils in aged animals during ischemic stroke observed in 
this study. To that end, we can examine whether promoting neutrophil return to 
the bone marrow (via agonistic engagement of the neutrophil bone marrow return 
receptor CXCR4,237 antagonistic engagement of the neutrophil bone marrow 
escape receptor CXCR2,238 or  exogenous addition of the bone marrow return 
chemokine CXCL12239 ) preferentially improves outcomes in aged animals after 
ischemic stroke.  
Neutrophil Priming & Hyperactivation. It is interesting to note that our data 
suggests that the stroke-induced increase in IL-6 and IL-8/CXCL1 (in mice and 
humans) and G-CSF (in mice) is augmented in the circulation of aged subjects. 
As reactive species hyperactivity was seen in circulating and brain-infiltrating 
neutrophils, but not present in bone marrow neutrophils, we hypothesized that 
the elevated levels of IL-6, CXCL1 and G-CSF found in the circulation of aged 
mice could prime neutrophils, enabling them to achieve higher levels of activation 
and reactive species production upon inflammatory stimulus (ex vivo PMA or in 
vivo ischemic stroke). In the future, a combination of in vivo and in vitro 
experiments may help to elucidate the role of these factors in the hyperactive 
reactive species phenotype of neutrophils in aged mice. Neutrophils isolated from 
the bone marrow of young and aged mice can be cultured with increasing 
amounts of IL-6, CXCL1 and G-CSF, and their reactive oxygen species 
production, NETosis and granule protein release can be assessed.  
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If our hypothesis is correct, and the hyperactivation seen in aged 
circulating neutrophils is due to the greater baseline levels of these factors in 
aged mice, we would expect to see increases in both young and aged neutrophil 
inflammatory responses after the addition of these factors. If these selected 
targets do not significantly increase neutrophil activation, we can then perform 
similar experiments using whole serum from young and aged mice (with or 
without stroke). If serum from aged animals increases neutrophil activation 
significantly compared to young animal serum, we can then perform screening 
assays (multiplex ELISA, proteomics analysis) to identify other potential serum 
factors driving the age-related increase in neutrophil activity.  
If the serum factors that contribute to neutrophil hyperactivation in aged 
animals are identified, we must then determine whether these neutrophil-
activating substances play a mechanistic role in the heightened pathogenicity of 
aged neutrophils in ischemic stroke. To that end, we can again use our inducible, 
neutrophil specific knockout model to inhibit expression of the receptors for each 
candidate factor (IL-6R for IL-6, CXCR2 for CXCL1 and G-CSF Receptor for G-
CSF, etc.). These experiments will allow us to determine whether the detrimental 
role of neutrophils in aged animals after stroke is dependent on the ability of 
neutrophils to respond to these factors. For more specific control over the timing 
of inhibition and to mimic future translational therapy, we can also utilize 
pharmacologic approaches to block these pathways,240-242 although this will 
result in less specific inhibition that may affect cells other than neutrophils. 
Excitingly, our lab has recently found that blockade of the IL-6 receptor 
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significantly improves outcome in aged male and female mice after stroke (data 
unpublished). Future experiments will examine whether the protective effect of 
IL-6R blockade is mediated in part by its effects on neutrophil function.  
 
Off-Target Chemotaxis. In other severe inflammatory injuries, such as 
sepsis, neutrophils have been reported to undergo “neutrophil paralysis”, during 
which their chemotaxis and adhesion molecule expression becomes 
deranged.243, 244 Rather than trafficking to the target tissue, neutrophils infiltrate 
the microvasculature of sensitive organs like the lung, liver and kidneys, 
mediating significant off-target tissue damage.245 As our neutrophil depletion 
studies found no significant effect on brain atrophy itself, it is possible that the 
improved outcome in aged mice was due to the suppression of deleterious off-
target organ damage. To this end, future experiments should analyze both the 
effects of age on neutrophil chemotaxis after stroke and the potential benefits of 
neutrophil depletion on off-target organ damage. 
 
 Neutrophil Clearance. As neutrophils themselves are short lived, they are 
hypothesized to undergo apoptosis within the injury site, after which they are 
cleared by macrophages.246 The purpose of this process, known as efferocytosis, 
is believed to be two-fold: to limit the noxious potential of neutrophil inflammatory 
functions and to stimulate the phenotypic shift of macrophage-like cells towards a 
pro-resolving, anti-inflammatory phenotype.247 Future studies should examine the 
impact of neutrophil depletion on the phenotype of the subsequent immune 
178		
response, particularly the phenotype of macrophages and monocytes 
(measureable by flow cytometry). As these cells have been shown to be integral 
to post-stroke tissue repair, it is possible that the high levels of efferocytosis 
stimulated in neutrophil depleted animals (as anti-Ly6G tagged neutrophils are 
cleared by macrophages) may favor a shift towards anti-inflammatory, pro-
restorative macrophage phenotypes within the brain.  
 
Neutrophils and Age-Related Stroke Comorbidities 
 One additional important factor to consider is that our aged mice tend to 
weigh significantly more than our young mice, driven largely by an increase in 
abdominal adipose tissue. Our lab has previously shown that these older mice 
have a higher incidence of hyperlipidemia and hyperglycemia than young mice. 
These chronic conditions, which are also more common in aged patients, could 
potentially contribute to the enhanced pathogenicity and pro-oxidative phenotype 
of neutrophils we see in our aged mice.  
Hyperlipidemia and hyperglycemia have been reported to contribute to 
chronic and excessive neutrophil activation, which is believed to further 
exacerbate tissue damage in chronic inflammatory conditions.98 Hyperglycemia, 
which often occurs with aging in both mice and humans, has been shown to 
increase neutrophil numbers in circulation and within wound sites, and to 
augment neutrophil ROS production, cytokine secretion and NETosis in 
patients.67, 248, 249  
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 Hyperlipidemia and obesity have been shown to result in a build-up of lipid 
metabolites and secondary inflammation throughout the body.250-253 Studies have 
previously shown that obesity is correlated with increased production of 
neutrophil-derived ROS, including superoxide.254-256 Recent work by Roberts et 
al. found that neutrophils from obese patients release significantly higher levels 
of ROS compared to neutrophils from controlled patients, which could be partially 
reduced by significant weight loss.257 
In light of the undeniable association between age and neutrophil-
activating comorbidities in human patients, future experimental work should 
assess whether conditions such as hyperlipidemia and hyperglycemia are (1) 
necessary and (2) sufficient for age-related increases in neutrophil pathogenicity 
after ischemic stroke. Fascinatingly, recent work in a mouse model has shown 
that induction of acute hyperglycemia in mice worsens outcomes and increases 
the likelihood of hemorrhagic transformation after ischemic stroke.258 Future work 
should explore whether the toxic effects of hyperglycemia are mediated by 
neutrophils by testing whether (1) the exacerbation of stroke outcomes in young 
animals by induced hyperglycemia can be reversed by neutrophil depletion and 
(2) whether controlling naturally occurring hyperglycemia in aged animals 
abrogates the efficacy of neutrophil depletion therapy.  
Similarly, a recent paper reported that genetic hyperlipidemia (ApoE 
knockout) exacerbates ischemic stroke damage in young mice, an effect that can 
be reversed by neutrophil depletion.259 A complimentary study should be 
performed in aged mice, with naturally occurring age-related hyperlipidemia 
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controlled via diet or pharmacology, to see whether the efficacy of neutrophil 
depletion is reduced in the absence of abnormal lipid levels.  
 
6.3 Significance and Impact 
 The aged population is growing rapidly worldwide, driving an increase in a 
wide variety of cardiovascular diseases like ischemic stroke.260, 261  First and 
foremost, this work highlights the importance of examining pathological 
processes and testing therapeutics in aged animal models, particularly when the 
target disease occurs largely in an aged population (e.g., cerebral ischemia, 
atherosclerosis, hypertension).  Although clinical epidemiology has always 
categorized stroke as a disease of aging, and a wealth of evidence has 
suggested that age alters many aspects of stroke pathophysiology, the majority 
of studies are still conducted in young, male animals.96, 262, 263 Adapting 
conclusions made from studies in young animals into treatments for aged 
humans is likely to significantly decrease the efficacy of clinical translation – and 
may mask the potential of age-dependent candidate therapies, like the anti-Ly6G 
antibody tested in Chapter 4 of this dissertation.  
Aging is known to have significant and profound effects on both the 
immune and cardiovascular systems.264 In particular, age-related changes in the 
function of neutrophils are now believed to be a significant mediator in many age-
related diseases.265 The body of work presented in this dissertation examines the 
utility of post-stroke neutrophil depletion therapy in young and aged animals and 
provides new insight into the changing function of injury-induced inflammation 
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throughout the lifespan. In addition, it shows that neutrophils from aged animals 
exhibit altered behaviors, including an impaired clearance phenotype, greater 
sensitivity to inflammatory stimulus and a higher capability for reactive species 
generation.  
While the studies included in this dissertation make a case for an age-
related increase in neutrophil pathogenicity after ischemic stroke, these 
implications of age-induced alterations in neutrophil biology are far-reaching, 
offering potential insight into the role of neutrophils in a variety of age-associated 
tissue injury and inflammatory processes, including atherosclerosis, cancer and 
autoimmune disease.  
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